<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Med</journal-id><journal-title>The Journal of Experimental Medicine</journal-title><issn pub-type="ppub">0022-1007</issn><issn pub-type="epub">1540-9538</issn><publisher><publisher-name>The Rockefeller University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9382888</article-id><article-id pub-id-type="pmc">2199152</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject><subj-group><subject>Articles</subject></subj-group></subj-group></article-categories><title-group><article-title>Qualitative Regulation of B Cell Antigen Receptor Signaling by CD19: Selective Requirement for PI3-Kinase Activation, Inositol-1,4,5-Trisphosphate Production and Ca<sup>2&#x0002b;</sup> Mobilization </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Buhl</surname><given-names>Anne Mette</given-names></name><xref ref-type="aff" rid="N0x1c46840N0x3c8af88">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Pleiman</surname><given-names>Christopher M.</given-names></name><xref ref-type="aff" rid="N0x1c46840N0x3c8af88">&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Rickert</surname><given-names>Robert C.</given-names></name><xref ref-type="aff" rid="N0x1c46840N0x3c8af88">&#x02016;</xref></contrib><contrib contrib-type="author"><name><surname>Cambier</surname><given-names>John C.</given-names></name><xref ref-type="aff" rid="N0x1c46840N0x3c8af88">&#x0002a;</xref><xref ref-type="aff" rid="N0x1c46840N0x3c8af88">&#x02021;</xref></contrib></contrib-group><aff id="N0x1c46840N0x3c8af88">From the <label>&#x0002a;</label>Division of Basic Sciences, Department of Pediatrics, National Jewish Medical and Research  Center, 1400 Jackson Street, Denver, Colorado 80206; <label>&#x02021;</label>Department of Immunology, University of  Colorado Health Sciences Center, Denver, Colorado 80206; <label>&#x000a7;</label>Cadus Pharmaceuticals, 1601 Pierce  St., Suite 110, Lakewood, Colorado 80214; and <label>&#x02016;</label>Department of Biology, University of California  San Diego, 9500 Gilman Drive, La Jolla, California 92093-0322</aff><author-notes><fn><p>Address correspondence to Dr. John C. Cambier, Division of Basic Sciences, Department of Pediatrics, National Jewish Research and Medical Center, 1400 Jackson St., Denver, CO 80206. Tel.: (303) 398-1325;  FAX: (303) 398-1225; E-mail: <email>cambierj&#x00040;njc.org</email></p></fn></author-notes><pub-date pub-type="ppub"><day>1</day><month>12</month><year>1997</year></pub-date><volume>186</volume><issue>11</issue><fpage>1897</fpage><lpage>1910</lpage><history><date date-type="received"><day>10</day><month>7</month><year>1997</year></date><date date-type="rev-recd"><day>19</day><month>9</month><year>1997</year></date></history><copyright-year>1997</copyright-year><abstract><p>Genetic ablation of the B cell surface glycoprotein CD19 severely impairs the humoral immune response. This requirement is thought to reflect a critical role of CD19 in signal transduction that occurs upon antigen C3dg coligation of antigen receptors with CD19 containing  type 2 complement receptors (CR2). Here we show that CD19 plays a key accessory role in B  cell antigen receptor signaling independent of CR2 coligation and define molecular circuitry  by which this function is mediated. While CD19 is not required for antigen-mediated activation of receptor proximal tyrosines kinases, it is critical for activation of phosphatidylinositol  3-kinase (PI3-kinase). PI3-Kinase activation is dependent on phosphorylation of CD19 Y484  and Y515. Antigen-induced CD19-dependent PI3-kinase activation is required for normal phosphoinositide hydrolysis and Ca<sup>2&#x0002b;</sup> mobilization responses. Thus, CD19 functions as a B cell antigen  receptor accessory molecule that modifies antigen receptor signaling in a qualitative manner.</p></abstract></article-meta></front><body><p>CD19 is a B-lymphocyte&#x02013;specific transmembrane glycoprotein that is expressed from the pro&#x02013;B cell until  the plasma cell stage. CD19 appears to function in multiple  capacities. It is a component of the type 2 complement receptor (CR2)<sup>1</sup> complex that contains CD19, CD21 (CR2),  CD81, (TAPA-1), and Leu-13. CR2 is expressed by mature B cells and is activated upon binding of C3dg (reviewed in reference <xref ref-type="bibr" rid="B1">1</xref>). Evidence indicates that CD19 may  also be a constitutive component of the B cell antigen receptor (BCR) complex and is phosphorylated upon BCR  crosslinking (<xref ref-type="bibr" rid="B2">2</xref>). Finally, although its ligand has not been  identified, CD19 appears to function as a transducer in  pro&#x02013; and pre&#x02013;B cells where it is expressed in the absence of  CD21 and the BCR. The function of CD19 in these various contexts is poorly understood.</p><p>CD19 is a highly conserved protein containing two immunoglobulin-like domains in its extracellular aspect and  nine potential tyrosine phosphorylation sites in its cytoplasmic tail (<xref ref-type="bibr" rid="B3">3</xref>). It is tyrosine phosphorylated upon cell activation in all three of the signaling contexts described above,  presumably by Lyn, Fyn, or Lck associated with unligated  CD19 (<xref ref-type="bibr" rid="B4">4</xref>&#x02013;<xref ref-type="bibr" rid="B8">8</xref>). After phosphorylation, tyrosines Y<sup>484</sup>XXM and  Y<sup>515</sup>XXM motifs have been shown to mediate the association of the p85-subunit of PI3-kinase with CD19 (<xref ref-type="bibr" rid="B9">9</xref>). In  addition the proto-oncogene product Vav has been shown  to associate with phosphorylated CD19 (<xref ref-type="bibr" rid="B10">10</xref>), presumably  through the Y<sup>393</sup>EEP motif which is predicted once phosphorylated to bind Vav (<xref ref-type="bibr" rid="B11">11</xref>). In vitro studies involving  CD19 coimmunoprecipitated from stimulated Ramos B  cells have demonstrated that tyrosine phosphorylated CD19  can interact with PI3-kinase, Fyn, PLC&#x003b3;1 and GAP SH2  domains suggesting the interaction of multiple signaling  molecules with the CD19 cytoplasmic tail (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>).</p><p>CD19 function has been studied primarily in the context  of its role as a member of the CR2 receptor complex (14&#x02013; 16). CD19 signal transduction is activated by binding of the  C3dg fragment of the C3 component of complement to  CD21. Coligation of CD19 or CD21 with BCR causes a  synergistic increase in a number of intracellular BCR-mediated signaling events, including Shc and Syk tyrosine phosphorylation (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>), PLC-activation and calcium mobilization (<xref ref-type="bibr" rid="B19">19</xref>). Coligation also lowers the threshold for antigen  stimulation of B cell proliferation (<xref ref-type="bibr" rid="B20">20</xref>) and enhances by  &#x02a7e;10,000-fold the immunogenicity of antigen&#x02013;complement  complexes (HEL-C3dg) (<xref ref-type="bibr" rid="B21">21</xref>).</p><p>Antibody crosslinking of CD19 on certain immature B cell  lines that do not express mIg has been shown to induce activation of Src-family kinases and tyrosine phosphorylation  of CD19 and Vav (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B22">22</xref>). In this context CD19 crosslinking also results in PLC-activation, calcium mobilization  and activation of the MAP kinase cascade (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B23">23</xref>).</p><p> Finally, anti-Ig stimulation of the BCR without CD19  cocrosslinking results in tyrosine phosphorylation of CD19,  indicating that CD19 is a target of BCR-activated kinases  (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B13">13</xref>). Also, anti-IgM stimulation of Daudi B cells leads  to an increase in CD19 association with PI3-kinase (<xref ref-type="bibr" rid="B9">9</xref>).  Consistent with this finding, several studies indicate that  CD19 may be physically associated with the BCR. Incubation of B cells with Ig-specific mAb leads to mIg and CD19  comodulation and cocapping (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>). In Daudi B cells CD19  can be coimmunoprecipitated with mIgM (<xref ref-type="bibr" rid="B2">2</xref>). Whether  CD21, Leu-13 and CD81 are required for the constitutive  association of CD19 with the BCR is unknown; however  CD19 expression levels in mature B cells appear to be  about fivefold higher than CD21 expression levels (<xref ref-type="bibr" rid="B14">14</xref>)  suggesting that CD19 occurs in both CD21-associated  and -nonassociated forms.</p><p>Recent production of CD19 knockout mice have provided an opportunity to analyze B cell function in the absence of CD19 (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>). B cell development appears normal in these mice, but humoral immune responses are  defective and B cells are unresponsive to antigen receptor  stimulation as indicated by proliferation.</p><p>In this study we have investigated the constitutive role of  CD19 in BCR-mediated signal transduction using CD19-deficient and -sufficient J558L&#x003bc;m3CD45<sup>&#x0002b;</sup> plasmacytoma  variants and primary B lymphocytes from CD19<sup>&#x02212;&#x0002f;&#x02212;</sup> and  CD19<sup>&#x0002b;/&#x0002b;</sup> mice. Our results demonstrate a critical role for  CD19 in antigen-mediated BCR activation of multiple signaling events. CD19 expression is required for detectable  BCR-mediated PI3-kinase activation and for maximal  phosphoinositide hydrolysis and calcium mobilization. The  latter effects appear causally linked to failed PI3-kinase activation. Other more subtle effects of CD19 on BCR signaling include increased antigen-mediated Lyn and Syk tyrosine phosphorylation, but these are not attributable to  enhanced PI3-kinase activation.</p><sec sec-type="materials|methods"><title>Materials and Methods</title><sec disp-level="3"><title>Reagents and Antibodies.</title><p>The murine B cell plasmacytoma  J558L&#x003bc;m3 was provided by M. Reth (Max-Planck Institute for  Immunology, Freiburg, Germany). We transfected this cell line  previously to obtain a mouse full-length (B220) CD45<sup>&#x0002b;</sup>-expressing variant (<xref ref-type="bibr" rid="B28">28</xref>). The human CD19 cDNA employed was provided by T. Tedder (Duke University Medical Center, Durham,  NC). Rabbit polyclonal antibodies against CD19, Ig &#x003b1;, Syk, and  Lyn, were prepared using GST fusion proteins produced in bacteria, purified by glutathione&#x02013;Sepharose chromatography and  cleaved with Factor Xa. Immunogens included the complete cytoplasmic tail for Ig&#x003b1;, residues 1-131 for Lyn, the linker region  for Syk (<xref ref-type="bibr" rid="B29">29</xref>), the SH3 domain for p85, and residues 411-547 of  the CD19 cytoplasmic tail. The polyclonal antibody to the p85  subunit of PI3-kinase and mixed mouse monoclonals to PLC&#x003b3;1  were purchased from UBI (Lake Placid, NY), anti-phosphotyrosine (AB-2) from Oncogene Science (Uniondale, NY), monoclonal anti-human CD19 from DAKO (Carpinteria, CA), and  rabbit polyclonal to PLC&#x003b3;2 from Santa Cruz Biochemicals (Santa  Cruz, CA). Rabbit F(ab&#x02032;)<sub>2</sub> antibody fragments to mouse IgG  (H&#x0002b;L) (F(ab&#x02032;)<sub>2</sub>RAMIG) was purchased from <named-content content-type="company" xlink:href="zymed">Zymed Labs</named-content>.  (South San Francisco, CA). HRP-conjugated protein A (<named-content content-type="company" xlink:href="zymed">Zymed)</named-content>  and rat anti&#x02013;mouse IgG1 (<named-content content-type="company" xlink:href="zymed">Zymed)</named-content> were used for detection using  the ECL detecting system (<named-content content-type="company" xlink:href="amersham">Amersham Corp.</named-content>, Arlington Heights,  IL). R-phycoerythrin conjugate (PE-streptavidin) was from Biosource (Camarillo, CA). Indo-1 AM was from Molecular Probes  Inc. (Eugene, OR). The inositol-1,4,5-trisphosphate [<sup>3</sup>H] radioreceptor assay kit and <italic>Myo</italic>-[2-<sup>3</sup>H(N)]-inositol (21.0 Ci/mmol) was  purchased from <named-content content-type="company" xlink:href="dupont">DuPont-NEN</named-content> (Boston, MA). Geneticin G418 was  from <named-content content-type="company" xlink:href="gibco">GIBCO BRL</named-content> (Gaithersburg, MD). Wortmannin was from  <named-content content-type="company" xlink:href="sigma">Sigma</named-content> Chem. Co. (St. Louis, MO). Nitrophenol (NP)<sub>9</sub>BSA was prepared by coupling of BSA (10 mg/ml) in 3% NaHCO<sub>3</sub> to NP-CAP-OSu (Cambridge Research Biochemicals, Cambridge, UK)  (40 mg/ml) in <italic>N</italic>,<italic>N</italic>-dimethyl formamide (DMF). After dialysis in  NaHCO<sub>3</sub> and PBS the molecular ratio of NP to BSA was determined  by measurement of the absorbance at OD<sub>430</sub> with an extinction  coefficient of 4230, pH 8.5 (NP molarity) and by Bradford analysis  (BSA molarity). CD19<sup>&#x02212;&#x0002f;&#x02212;</sup> mice (<xref ref-type="bibr" rid="B27">27</xref>) were provided by R.C. Rickert  and K. Rajewsky (University of Cologne, Cologne, Germany).</p></sec><sec disp-level="3"><title>Cell Culture and Infection.</title><p>The human CD19 cDNA was isolated from pMT2 by EcoR1 digest and subcloned into pSK Bluescript (Stratagene Inc., La Jolla, CA). The CD19 cDNA was then  removed from pSK with HindIII/ClaI restriction digest and cloned  into pLNCX (Williams, Fred Hutchinsen Cancer Center, Seattle,  WA). This construct was electroporated into GP&#x0002b;E/NIH3T3 cells  and cell supernatant collected at 72 h. To increase the virus titer,  GP&#x0002b;E/NIH3T3 cells were incubated for 12 h in tunicamycin  (1 &#x003bc;g/ml), and reinfected with pLNCX/hCD19 retrovirus by incubating with the cell supernatant collected above. After G418  selection (1 mg/ml), virus expressing clones were selected. Virus collected from these cells was then used to infect J558L&#x003bc;mCD45<sup>&#x0002b;</sup>  myeloma cells. Polyclonal human CD19 positive J558L&#x003bc;m  3CD45<sup>&#x0002b;</sup> cells were obtained after G418 selection by cell sorting  of the bulk-infected population with a mouse monoclonal to human CD19. The cells were propagated in IMDM supplemented  with 5% heat inactivated FCS (Hyclone Labs. Inc., Logan, UT),  50 U/ml penicillin and 50 &#x003bc;g/ml streptomycin and 1 mg/ml  G418 (J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>CD19<sup>&#x0002b;</sup>) at 37&#x000b0;C with 7% CO<sub>2</sub>. Mutation  of CD19 tyrosines 484 and 515 to phenylalanines was performed  by PCR using the primers TCCCAGTCCTTTGAGGATATG/ CATATCCTCAAAGGACTGGGA for Y<sup>484</sup> and GCAGACTCTTTTGAGAACATG/CATGTTCTCAAAAGAGTCTGC for Y<sup>515</sup>.  Mutated CD19 was inserted into pLNCX, packaged and used for  infection as described above.</p></sec><sec disp-level="3"><title>Analysis of Protein Tyrosine Phosphorylation.</title><p>For stimulation cells  were harvested, washed once in IMDM and resuspended at 10<sup>7</sup>  cells/ml in IMDM. After 5 min incubation at 37&#x000b0;C, cells were  stimulated with NP<sub>9</sub>BSA (2.5 &#x003bc;g/ml), pelleted in a picofuge,  resuspended in lysis buffer (10 mM Tris, pH 7.5, 150 mM NaCl, 1  mM EDTA, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 10 mM NaF, 1% NP-40, 1 mM  PMSF, and 2 &#x003bc;g/ml each of leupeptin, aprotinin, and &#x003b1;-1 antitrypsin), and then incubated on ice for 10 min. Lysates were centrifuged for 5 min at 14,000 rpm. Cleared lysates were incubated  with antibodies to signaling molecules and protein A&#x02013;Sepharose or  protein G&#x02013;Sepharose at 4&#x000b0;C, washed four times in lysis buffer,  boiled with reducing SDS sample buffer, and then fractionated on  10% SDS-PAGE. SDS-PAGE&#x02013;fractionated proteins were subjected to electrophoretic transfer to PVDF membranes. Transfers  were probed with antibodies and developed using the ECL detection system. Sequential immunoblotting for phosphotyrosine  and effector was performed. For this purpose PVDF membranes  were stripped in stripping buffer (100 mM 2-mercaptoethanol,  2% SDS, 62.5 mM Tris-HCl, pH 6.7) for 30 min at 54&#x000b0;C,  washed and blocked before immunoblotting.</p></sec><sec disp-level="3"><title>Flow Cytometric Analysis of [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> Mobilization.</title><p>Cells were loaded  with indo-1 AM and the intracellular [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> was monitored by  flow cytometry (model 50H; Ortho Diagnostic Systems, Westwood, MA) as previously described (<xref ref-type="bibr" rid="B28">28</xref>). The mean [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> and  percent of cells responding was determined with an appended  data acquisition system and the MultiTIME software (Phoenix  Flow Systems, San Diego, CA).</p></sec><sec disp-level="3"><title>Measurement of Inositol Phosphate Generation.</title><p>Inositol-1,4,5-trisphosphate generation was measured using a [<sup>3</sup>H] radioreceptor  assay kit (<named-content content-type="company" xlink:href="dupont">DuPont-NEN</named-content>) according to the manufacturer's instructions. Generation of total inositol phosphates was measured as follows: cells were labeled for 18 h in 2 &#x003bc;Ci/ml of <italic>myo</italic>-[2-<sup>3</sup>H(N)]- inositol in inositol-free medium containing dialyzed 5% FCS  before being washed in inositol-free media and incubated with  inositol-free media containing 20 mM LiCl for 5 min. Cells were  then stimulated for 25 min, lysed in 2 ml of methanol/HCl (99:1),  and then 2 ml of chloroform was added. The aqueous phase was  extracted, applied to a formate anion-exchange column, and then  inositol phosphates were eluted with elution buffer (0.1 M formic  acid, 1.0 M ammonium formate). Total [<sup>3</sup>H] inositol incorporation  was determined by measuring the radioactivity in the organic phase.</p></sec><sec disp-level="3"><title>Assay for PI3-Kinase Activity.</title><p>Cells were stimulated, lysed,  and then immunoprecipitated for 1 h at 4&#x000b0;C using anti-p85 antibodies and protein A&#x02013;Sepharose. PI3-kinase activity was measured  as previously described (<xref ref-type="bibr" rid="B30">30</xref>). Samples were dried and reaction  products resolved by thin-layer chromatography on precoated  TLC Silica Gel 60 plates in CHCl<sub>3</sub>/MeOH/2.5 M NH<sub>4</sub>OH (9:7: 2). The incorporation of <sup>32</sup>PO<sub>4</sub> into phosphatidylinositol 3-phosphate was determined using a PhosphorImager.</p></sec><sec disp-level="3"><title>Isolation of Splenic B Cells.</title><p>Splenic B cells were prepared as  previously described (<xref ref-type="bibr" rid="B31">31</xref>). In brief, spleens were excised from mice  and cells were dispersed through a 100-&#x003bc;m mesh in IMDM. Red  blood cells were lysed using Gey's solution. Total nucleated spleen  preparations were depleted of T lymphocytes by complement-mediated lysis using HO13.4 and T24 antibodies and dense cells  (&#x003c1; &#x02a7e;1.066) isolated by discontinuous Percoll density gradient  centrifugation.</p></sec></sec><sec><title>Results</title><p>Although tyrosine phosphorylation of CD19 after BCR  ligation is well documented, the contribution of CD19 to  BCR signaling is not defined. To study the role of CD19  in antigen-induced signal transduction we generated a  wild-type CD19-positive and Y<sup>484/Y515</sup> to F CD19-positive  variant of the J558L&#x003bc;m3CD45<sup>&#x0002b;</sup> plasmacytoma. The parent  clone expresses a NP-specific BCR and CD45, but does  not express CD19 (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B32">32</xref>). Human CD19 (hCD19) was  introduced into this clone by retroviral infection, and lines  (polyclonal populations) were isolated by G418 selection  and fluorescence activated cell sorting of cells. Flow cytometric analysis revealed similar expression levels of sIgM,  CD45 and CD19 in the plasmacytoma cell lines (Fig. <xref ref-type="fig" rid="F1">1</xref>).  Human CD19 was utilized since antibodies to mouse CD19  were not available at the time the studies were undertaken,  and human and mouse CD19 are highly homologous (79%  in nucleotide sequence, 75% in amino acid sequence) particularly in the cytoplasmic domain (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B33">33</xref>). Recent studies  indicate that human CD19 complements B cell function in  CD19<sup>&#x02212;&#x0002f;&#x02212;</sup> mice (<xref ref-type="bibr" rid="B34">34</xref>). In addition, using a recently generated  rat mAb, 1D3, specific for murine CD19 (<xref ref-type="bibr" rid="B35">35</xref>), Krop et al.  (<xref ref-type="bibr" rid="B22">22</xref>) have demonstrated that murine CD19 shares with human CD19 an association with complement receptor CD21  and CD81, tyrosine phosphorylation, binding of PI3-kinase,  and synergistic signaling with membrane IgM. </p><sec disp-level="4"><title>Antigen-stimulated Intracellular Ca<sup>2&#x0002b;</sup> Release and Extracellular Ca<sup>2&#x0002b;</sup> Influx Is Increased in Cells Expressing CD19.</title><p>To investigate the differences in BCR signaling in the CD19-negative and -positive contexts, we loaded the J558L&#x003bc;m3  CD45<sup>&#x0002b;</sup>CD19-negative and CD19-positive variants with  indo-1 AM and analyzed changes in intracellular free calcium concentration ([Ca<sup>2&#x0002b;</sup>]<sub>i</sub>) in response to antigen stimulation. Initially, this was done under conditions where the  free calcium concentration in the medium ([Ca<sup>2&#x0002b;</sup>]<sub>o</sub>) was  maintained at physiological levels of 1.3 mM. As shown in  Fig. <xref ref-type="fig" rid="F2">2</xref> (<italic>solid lines</italic>), antigen stimulation induced a rise in  [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> in both cell lines; in the CD19-positive cell line the  maximal mean [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> reached 430 nM while it was 260 nM  in the CD19-negative cells. In the CD19-positive cell line,  antigen stimulation also induced a much more prolonged  increase in [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> than in the CD19-negative clone. To  determine whether intracellular or extracellular calcium was  responsible for the respective [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> increases, we added  3 mM EGTA at the time of initiation of analysis of [Ca<sup>2&#x0002b;</sup>]<sub>i</sub>.  This results in buffering of [Ca<sup>2&#x0002b;</sup>]<sub>o</sub> to a concentration of  65 nM (which corresponds to the [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> in resting cells)  and prevents influx of extracellular calcium into the cell.  Comparison of antigen-induced responses of CD19-negative and CD19-positive cells in low [Ca<sup>2&#x0002b;</sup>]<sub>o</sub> (Fig. <xref ref-type="fig" rid="F2">2</xref>, <italic>dotted  lines</italic>) indicated that optimal receptor-mediated release of  calcium from intracellular stores requires CD19. Comparison of responses in high [Ca<sup>2&#x0002b;</sup>]<sub>o</sub> revealed that influx is also  dependent on the expression of CD19 (Fig. <xref ref-type="fig" rid="F2">2</xref>, <italic>solid lines</italic>). </p></sec><sec disp-level="4"><title>Antigen Stimulation of Inositol-1,4,5-trisphosphate (IP<sub>3</sub>) Production Is Dependent on CD19 Expression.</title><p>To study CD19  dependence of signaling events upstream from calcium mobilization, we first compared antigen stimulation of IP<sub>3</sub>  production in CD19-positive and -negative cells. IP<sub>3</sub> binds  to its receptors on the ER leading to release of Ca<sup>2&#x0002b;</sup> into  the cytoplasm. Emptying of the ER stores triggers entry of  calcium from the extracellular space by a mechanism  known as capacitative Ca<sup>2&#x0002b;</sup> entry (<xref ref-type="bibr" rid="B36">36</xref>). Thus, CD19 dependence of IP<sub>3</sub> generation-induced response by antigen could  explain the dependence of both intracellular calcium release  and extracellular calcium influx on CD19 expression. Stimulation of the cell lines led to a very rapid and sustained rise  in IP<sub>3</sub> production in the CD19-positive clone as measured  using an IP<sub>3</sub>-receptor binding inhibition assay (Fig. <xref ref-type="fig" rid="F3">3</xref> <italic>A</italic>).  Antigen stimulation of the CD19-negative clone led to rapid,  but much more modest and only transient generation of  IP<sub>3</sub>. The kinetics and magnitude of IP<sub>3</sub> generation was consistent with those of calcium mobilization responses shown  in Fig. <xref ref-type="fig" rid="F2">2</xref> supporting the possibility that the attenuated calcium mobilization response may be caused by the attenuated BCR-mediated hydrolysis of PIP<sub>2</sub>. We also measured  the generation of [<sup>3</sup>H]-inositol mono- and polyphosphates  after antigen stimulation of <italic>myo</italic>-[2-<sup>3</sup>H(N)]-inositol&#x02013;labeled  cell lines. As shown in Fig. <xref ref-type="fig" rid="F3">3</xref> <italic>B</italic> the fold increase in total  inositol mono- and polyphosphates generated during a 25-min stimulation was consistent with the mass measurement  of IP<sub>3</sub> production (Fig. <xref ref-type="fig" rid="F3">3</xref> <italic>A</italic>); stimulation of the CD19-positive clone led to an &#x0223c;250% increase in inositol phosphate  generation, while stimulation of the CD19-negative cell  line induced an &#x0223c;30% increase. </p></sec><sec disp-level="4"><title>CD19 Expression Enhances BCR-mediated Protein Tyrosine  Phosphorylation.</title><p>Antigen stimulation is known to induce  recruitment of Src- and Syk-family tyrosine kinases to Ig-&#x003b1;  and Ig-&#x003b2; components of the BCR (<xref ref-type="bibr" rid="B37">37</xref>&#x02013;<xref ref-type="bibr" rid="B39">39</xref>). The tyrosine  kinases bind via their SH2-domains to immunoreceptor tyrosine based activation motif (ITAM) phosphotyrosines and  this leads to secondary recruitment, phosphorylation, and  activation of downstream signaling molecules such as PLC&#x003b3;1,  PLC&#x003b3;2, and PI3-kinase (reviewed in reference <xref ref-type="bibr" rid="B40">40</xref>). To define the effects of CD19 expression on these phosphorylation events we stimulated CD19-negative and -positive cell  lines, immunoprecipitated intracellular signaling molecules  and conducted anti-phosphotyrosine immunoblotting analysis. The spectra of phosphoproteins in whole cell lysates from  the J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>CD19<sup>-</sup> and the J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>  CD19<sup>&#x0002b;</sup> cell lines looked similar with the exception of the  presence of a tyrosine phosphorylated CD19 in the CD19-positive cell lysate (results not shown). Induced phosphorylation of several signaling molecules was analyzed after  stimulation with normalization of immunoprecipitation and  lane loading by sequential antieffector immunoblotting.  We studied tyrosine phosphorylation after 1 min of antigen  stimulation since we have shown previously that effector  enzymes under study are maximally phosphorylated at this  time in the J558L&#x003bc;m3CD45<sup>&#x0002b;</sup> plasmacytoma (<xref ref-type="bibr" rid="B41">41</xref>). As shown  in Fig. <xref ref-type="fig" rid="F4">4</xref>, CD19 expression led to modest increases in antigen-induced tyrosine phosphorylation of Ig-&#x003b1;, Lyn, Syk,  PLC&#x003b3;1, and PLC&#x003b3;2. Quantitation of tyrosine phosphorylation by scanning densitometry (at least three independent  experiments for each effector enzyme) and normalization  to effector levels revealed increased phosphorylation of Ig-&#x003b1;,  Lyn, and Syk by 1.5&#x02013;2-fold in the CD19-positive line. Induced PLC&#x003b3;1 and PLC&#x003b3;2 tyrosine phosphorylation was  2.5&#x02013;3-fold higher in the CD19-positive cell line than in  the CD19-negative cell line. These results suggest that  CD19 functions in part by increasing the magnitude of certain proximal BCR coupled tyrosine phosphorylation events. </p></sec><sec disp-level="4"><title>Antigen Stimulation of PI3-Kinase Activation Is Severely Impaired in the CD19-negative J558L&#x003bc;m3CD45<sup>&#x0002b;</sup> Plasmacytoma.</title><p>CD19 contains two cytoplasmic YXXM motifs that  mediate its association with the p85 subunit of PI3-kinase  after phosphorylation of the tyrosines (<xref ref-type="bibr" rid="B9">9</xref>). The phosphorylation of these tyrosines may contribute to BCR-mediated  PI3-kinase activation. We determined the activity of PI3-kinase in the cell lines by measuring the PI3-kinase activity  associated with anti-p85 immunoprecipitates after stimulation with NP<sub>9</sub>BSA for 2 min. The results shown in Fig. <xref ref-type="fig" rid="F5">5</xref>  demonstrate a 250% increase in PI3-kinase activity in the  CD19-positive cell line after antigen stimulation, but only  a 40% increase in the CD19-negative variant. The residual  activation of PI3-kinase in the absence of CD19 expression  is probably a result of PI3-kinase activation through interaction with SH3 domains of Src-family kinases (<xref ref-type="bibr" rid="B42">42</xref>). The  results described above are summarized in the two first columns of Table <xref ref-type="table" rid="T1">1</xref>. It is clear that CD19 influences multiple  intracellular signaling events. Some signaling events are  only slightly increased in the CD19-positive cell line, (i.e.,  Ig-&#x003b1;, Lyn, and Syk tyrosine phosphorylation) while others  are almost totally dependent on expression of CD19 (i.e.,  IP<sub>3</sub> generation, calcium influx, and PI3-kinase activation).  </p></sec><sec disp-level="4"><title>Wortmannin Inhibits Antigen-induced [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> Mobilization  and IP<sub>3</sub> Generation in the J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>CD19<sup>&#x0002b;</sup> Plasmacytoma.</title><p>To begin to dissect the relationship among the  observed CD19 effects, we assessed the effects of the PI3-kinase inhibitor wortmannin on signaling events. Wortmannin has been shown to inhibit PI3-kinase activity by  covalent modification of a lysine residue in the PI3-kinase  catalytic subunit, p110 (<xref ref-type="bibr" rid="B43">43</xref>). We also used the competitive  PI3-kinase inhibitor Ly294002 (<xref ref-type="bibr" rid="B44">44</xref>) and obtained similar  results as in our studies with wortmannin (results not shown).  The effect of wortmannin on antigen-induced activation of  PI3-kinase was determined. The results shown in Fig. <xref ref-type="fig" rid="F6">6</xref> <italic>A</italic>  demonstrate the inhibitory effect of wortmannin on antigen-mediated PI3-kinase activation in the J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>  CD19<sup>&#x0002b;</sup> plasmacytoma. Cells were pretreated for 30 min with  DMSO (vehicle) or increasing concentrations of wortmannin, stimulated with antigen for 2 min, washed, and then  lysed before PI3-kinase was immunoprecipitated and activity measured in an in vitro kinase assay with phosphatidylinositol (PI) containing vesicles as substrate. Consistent with its  previously established IC<sub>50</sub>, 10 nM wortmannin inhibited  the antigen-mediated PI3-kinase activation by 54%, and 25  nM wortmannin inhibited 75% of antigen-induced PI3-kinase  activity. Wortmannin added to the cells immediately before washing and lysis did not effect the PI3-kinase activity  (data not shown) indicating that the inhibitor was acting  intracellularly. </p><p>To investigate the influence of PI3-kinase on the BCR-mediated calcium mobilization seen in the CD19-positive  cell line, we preincubated the cells with increasing concentrations of wortmannin and measured the antigen-induced  increase in [Ca<sup>2&#x0002b;</sup>]<sub>i</sub>. As shown in Fig. <xref ref-type="fig" rid="F6">6</xref> <italic>B</italic>, wortmannin  strongly inhibited Ca<sup>2&#x0002b;</sup> mobilization in the J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>  CD19<sup>&#x0002b;</sup> cells. Sensitivity to wortmannin was also evident in  the IP<sub>3</sub> generation response. A wortmannin concentration of  25 nM strongly inhibited IP<sub>3</sub> production in the J558L&#x003bc;m3  CD45<sup>&#x0002b;</sup>CD19<sup>&#x0002b;</sup> cell line after 1 minute of antigen stimulation (Fig. <xref ref-type="fig" rid="F6">6</xref> <italic>C</italic>). In both cases wortmannin at a concentration of 25 nM converted the phenotype of the CD19-positive cells essentially to that of the CD19-negative cells. This  result was consistent with the 75% inhibition of PI3-kinase  activation by 25 nM wortmannin in Fig. <xref ref-type="fig" rid="F6">6</xref> <italic>A</italic> and indicates  that the CD19 requirement for IP<sub>3</sub> production and calcium  mobilization may be attributable to PI3-kinase activation.  Interestingly, wortmannin inhibited the residual antigen-stimulated PI3-kinase activation, IP<sub>3</sub> production, and Ca<sup>2&#x0002b;</sup>  mobilization of the CD19-negative cell line (data not shown)  consistent with the possible absolute dependence of these  responses on PI3-kinase activation.</p></sec><sec disp-level="4"><title>Induced Tyrosine Phosphorylation of Intracellular Effector Enzymes Is Insensitive to Wortmannin.</title><p>To investigate the potential role of CD19-activated PI3-kinase on early BCR-mediated protein tyrosine phosphorylation events, CD19-positive cells were preincubated for 30 min with DMSO  (vehicle) or increasing concentrations of wortmannin and  stimulated for 1 min with antigen before effectors were immunoprecipitated and analyzed. As shown in Fig. <xref ref-type="fig" rid="F7">7</xref>, antigen-induced tyrosine phosphorylation of Ig-&#x003b1;, Lyn, and  Syk was insensitive to wortmannin. PLC&#x003b3;1 and PLC&#x003b3;2 tyrosine phosphorylation was somewhat sensitive to wortmannin preincubation although the decrease in induced tyrosine phosphorylation was modest (35% inhibition at 25 nM  wortmannin, Table <xref ref-type="table" rid="T2">2</xref>) compared with the degree of wortmannin inhibition of IP<sub>3</sub> generation and calcium mobilization (91.5% inhibition, Table <xref ref-type="table" rid="T2">2</xref>). It seems very unlikely that  the &#x0003e;90% inhibition of PLC&#x003b3; activity could be caused by a  35% inhibition of PLC&#x003b3; phosphorylation Thus, as summarized in Table <xref ref-type="table" rid="T1">1</xref>, CD19 expression by the J558L&#x003bc;m3  CD45<sup>&#x0002b;</sup> plasmacytoma is required for optimal antigen stimulation of multiple intracellular signaling events, but only  some of these are secondary to the nearly absolute dependence of PI3-kinase activation on CD19.  </p></sec><sec disp-level="4"><title>Mutation of p85 Binding Sites Destroy the Ability of CD19  to Mediate an Increase in BCR-mediated [Ca<sup>2&#x0002b;</sup>]<sub>i </sub>Mobilization.</title><p>To further explore the requirement of CD19 for  PI3-kinase activation and optimal antigen-mediated [Ca<sup>2&#x0002b;</sup>]<sub>i</sub>  mobilization, we introduced a double-point mutant of  CD19, CD19Y<sup>484</sup>F,Y<sup>515</sup>F, into the J558L&#x003bc;m3CD45<sup>&#x0002b;</sup> plasmacytoma. The expression levels of sIgM, CD45 and CD19  (Y<sup>484</sup>F,Y<sup>515</sup>F) in this cell line is shown in Fig. <xref ref-type="fig" rid="F1">1</xref>. It has previously been demonstrated that the mutations Y<sup>484</sup>F and  Y<sup>515</sup>F abrogates the ability of CD19 to interact with the  p85-subunit of PI3-kinase (<xref ref-type="bibr" rid="B9">9</xref>). Like the CD19-negative cell  line, the CD19 mutant cell line, showed no significant antigen-mediated activation of PI3-kinase (results not shown).  When we assayed the ability of the cell line expressing the  mutant CD19 to mobilize [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> in response to antigen  stimulation, we found that the mutant CD19 cell line behaved equivalently to the J558L&#x003bc;m3CD45<sup>&#x0002b;</sup> cell line (Fig.  <xref ref-type="fig" rid="F8">8</xref>). This suggests that both CD19-mediated increase in  BCR-induced PI3-kinase activation and Ca<sup>2&#x0002b;</sup> mobilization  require phosphorylation of CD19 Y<sup>484</sup> and Y<sup>515</sup>. </p></sec><sec disp-level="4"><title>Wortmannin Inhibits Antigen-stimulated [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> Mobilization in Splenic B Cells.</title><p>To investigate the role of PI3-kinase  in antigen-induced signaling in a more physiological system, we purified splenic B cells (&#x003c1; &#x02a7e;1.066) from spleens of  normal mice and assessed the effects of wortmannin on  BCR signaling. After preincubation for 30 min with DMSO  or wortmannin, splenic B cells were stimulated with 13.2  &#x003bc;g/10<sup>6</sup> cells F(ab&#x02032;)<sub>2</sub>RAMIG. As observed in the J558L  &#x003bc;m3CD45<sup>&#x0002b;</sup>CD19<sup>&#x0002b;</sup> cell line, wortmannin inhibited, as a  function of its concentration, the antigen-mediated calcium  mobilization in these primary B cells (Fig. <xref ref-type="fig" rid="F9">9</xref>). Wortmannin  also inhibited the residual antibody-mediated Ca<sup>2&#x0002b;</sup> mobilization in CD19<sup>&#x02212;&#x0002f;&#x02212;</sup> splenic B cells (data not shown). Thus,  BCR signaling in J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>CD19<sup>&#x0002b;</sup> and normal B  cells is similarly sensitive to PI3-kinase inhibition and  CD19 function (see below). </p></sec><sec disp-level="4"><title>CD19 Is Required for Anti-BCR Stimulation of PI3-Kinase  Activation and Ca<sup>2&#x0002b;</sup> Mobilization in Splenic B Cells.</title><p>To extend our observations regarding CD19 dependence of BCR-mediated signaling in B lymphocytes we compared BCR-mediated PI3-kinase activation and calcium mobilization  responses of B cells from CD19 knockout mice and normal  mice. It has previously been reported that no distinguishable difference can be seen between CD19-deficient and  normal B cells in the pattern or the degree of substrate phosphorylation after surface immunoglobulin stimulation (<xref ref-type="bibr" rid="B27">27</xref>).  We obtained the same results when comparing whole cell  lysates from CD19<sup>&#x02212;&#x0002f;&#x02212;</sup> and CD19<sup>&#x0002b;&#x0002f;&#x0002b;</sup> cells (results not shown).  However, careful investigation of several signaling events  revealed that &#x003c1; &#x02a7e;1.066 resting splenic B lymphocytes from  CD19<sup>&#x02212;&#x0002f;&#x02212;</sup> mice are impaired in their response to surface immunoglobulin crosslinking when compared with CD19<sup>&#x0002b;/&#x0002b;</sup>  littermates. F(ab&#x02032;)<sub>2</sub>RAMIG-mediated PI3-kinase activation  was severely diminished in the CD19<sup>&#x02212;&#x0002f;&#x02212;</sup> B cells (Fig. <xref ref-type="fig" rid="F10">10</xref>),  reminiscent of the situation in the plasmacytoma cell lines.  As shown in Fig. <xref ref-type="fig" rid="F11">11</xref>, absence of CD19 also clearly affects  BCR-mediated calcium mobilization. A decrease in calcium mobilization was seen in B lymphocytes from the  CD19<sup>&#x02212;&#x0002f;&#x02212;</sup> mice in response to stimulation with an optimal  dose of antibody (Fig. <xref ref-type="fig" rid="F11">11</xref> <italic>A</italic>). At suboptimal concentrations  of antibody (1.3 &#x003bc;g F(ab&#x02032;)<sub>2</sub>RAMIG) almost no BCR-mediated calcium mobilization was seen in cells from CD19<sup>&#x02212;&#x0002f;&#x02212;</sup>  mice, while cells from the CD19<sup>&#x0002b;/&#x0002b;</sup> littermates still responded well (Fig. <xref ref-type="fig" rid="F11">11</xref> <italic>B</italic>). We obtained equivalent results in  10 independent experiments. Our results appear to conflict  with those of Sato et al.(34), who observed enhancement  of later phase Ca<sup>2&#x0002b;</sup> mobilization in CD19<sup>&#x02212;&#x0002f;&#x02212;</sup> cells. These  contrasting findings may result from technical differences in  the respective studies.  </p></sec></sec><sec><title>Discussion</title><p>Recent studies of CD19<sup>&#x02212;&#x0002f;&#x02212;</sup> mice and CD19 transgenic  mice have demonstrated the importance of CD19 in B cell  development, but particularly in the immune response of  mature B cells. In human CD19 transgenic mice B cell development is impaired (<xref ref-type="bibr" rid="B45">45</xref>) as indicated by the fact that  these mice have dramatically fewer B cells in the periphery.  In these transgenic animals proper B cell development is  very sensitive to even small increases in CD19 expression  levels (<xref ref-type="bibr" rid="B46">46</xref>). CD19<sup>&#x02212;&#x0002f;&#x02212;</sup> mice also have lower levels of B cells  in the periphery, and mature B cells from these animals  mount a poor proliferative response to anti-BCR antibodies. These animals respond only weakly to T cell&#x02013;dependent  antigens, germinal center formation is lacking or diminished, and the serum immunoglobulin levels are significantly reduced (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B47">47</xref>). Based on these findings, it has  been suggested that CD19 functions by enhancing the cellular sensitivity to antigen, setting the threshold for antigen-mediated signaling (<xref ref-type="bibr" rid="B46">46</xref>). This may reflect a CR2-dependent  coreceptor function and/or an accessory function of CD19  in BCR signal transduction.</p><p>Here we have defined an important accessory function  for CD19 in antigen-induced BCR signal transduction and  described a molecular basis for this accessory function.  CD19 was found to influence the magnitude of activation  of multiple intracellular signaling pathways after antigen  stimulation of the BCR. While expression of CD19 leads to  modestly enhanced antigen-induced Ig-&#x003b1;, Lyn, Syk, PLC&#x003b3;1,  and PLC&#x003b3;2-inductive tyrosine phosphorylation, CD19 is  absolutely required in order to obtain substantial PI3-kinase  activation, IP<sub>3</sub> generation, and maximal calcium mobilization. Thus, CD19 modifies BCR signaling in a qualitative  manner. Using the PI3-kinase inhibitor wortmannin we  further determined that while the increased antigen-induced  tyrosine phosphorylation of Ig-&#x003b1;, Lyn, and Syk is independent of PI3-kinase activation, differences in IP<sub>3</sub> turnover  and calcium mobilization are a function of PI3-kinase activation. Results obtained in CD19-positive and -negative  variants of the J558L&#x003bc;m3CD45<sup>&#x0002b;</sup> plasmacytoma cells were  confirmed using primary B lymphocytes from CD19<sup>&#x02212;&#x0002f;&#x02212;</sup>  mice and wild-type littermates. Thus, CD19 functions in  promoting BCR-mediated phosphoinositide hydrolysis via  activation of PI3-kinase, and also supports antigen-induced  phosphorylation of BCR receptor components and receptor  activated kinases by an unknown mechanism. Since the src-family kinases Lyn and Lck are found associated with CD19  in unstimulated cells (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>), CD19 may mediate the latter  effect via an increase in Ig-&#x003b1; phosphorylation by these kinases.</p><p> It has been demonstrated previously that wortmannin  can inhibit angiotensin II&#x02013;mediated IP<sub>3</sub> production in adrenal glomerulosa cells (<xref ref-type="bibr" rid="B48">48</xref>) as well as anti-DNP-IgE&#x02013;mediated IP<sub>3</sub> production in RBL-2H3 cells (<xref ref-type="bibr" rid="B49">49</xref>). The mechanisms by which PI3-kinase affects inositol lipid hydrolysis is  unclear. PLC&#x003b3;1 and PLC&#x003b3;2 are highly homologous enzymes; both contain two SH2 domains and one SH3 domain. In vitro studies suggest that tyrosine phosphorylation  of the enzymes is required to increase the catalytic activity,  but phosphatase treatment of phosphorylated PLC&#x003b3;1 only  partially inhibits PLC&#x003b3;1-mediated inositol trisphosphate  production (<xref ref-type="bibr" rid="B50">50</xref>), indicating that mechanisms other than tyrosine phosphorylation may regulate PLC&#x003b3;1 activation. Our  studies using the PI3-kinase inhibitor, wortmannin, indicate that antigen-stimulated inositol lipid turnover and calcium mobilization are dependent on PI3-kinase activation  in B cells. Interestingly, induction of PLC&#x003b3;1 and PLC&#x003b3;2  tyrosine phosphorylation is relatively insensitive to wortmannin. As shown in Table <xref ref-type="table" rid="T2">2</xref>, IP<sub>3</sub> production is substantially inhibited by 10 nM wortmannin, while this concentration of wortmannin has a neglectable effect on PLC&#x003b3;1 and  PLC&#x003b3;2 tyrosine phosphorylation. PI3-kinase phosphorylates  the phosphoinositol containing lipids; PI, PI(4)P and  PI(4,5)P<sub>2</sub> at the D3 position of the inositol ring (<xref ref-type="bibr" rid="B30">30</xref>). Two  of the products of this phosphorylation, PI(3,4)P<sub>2</sub> and  PI(3,4,5)P<sub>3</sub>, are important regulators of cell proliferation  (<xref ref-type="bibr" rid="B51">51</xref>). Recently it was suggested that PI(3,4,5)P<sub>3</sub> may play a  role in signaling by associating with SH2 domains, and thereby  modulating PI3-kinase association with tyrosine phosphorylated proteins (<xref ref-type="bibr" rid="B52">52</xref>). PI(3,4,5)P<sub>3</sub> could thereby regulate the  activity of SH2 containing effector enzymes either directly  or indirectly by relocating them. We suggest that this may  reflect PI(3,4,5)P<sub>3</sub>, the product of PI3-kinase, association  with the SH2 domain of PLC&#x003b3;1 and translocation of the  enzyme to the plasma membrane where its substrate resides. Indeed addition of PI(3,4,5)P<sub>3</sub> to substrate vesicles has  been shown to increase PLC&#x003b3; hydrolysis of PI(4,5)P<sub>2</sub> (<xref ref-type="bibr" rid="B53">53</xref>).  It has been demonstrated in other cell types that cell stimulation results in translocation of PLC&#x003b3;1 and PLC&#x003b3;2 from  the cytosol to the membrane (<xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B55">55</xref>). This suggests that  activation of phosphatidylinositol hydrolysis involves both  a PLC&#x003b3; tyrosine phosphorylation event and a translocation  event. Alternatively, or additionally, interactions between  PI(3,4,5)P<sub>3</sub> and pleckstrin homology (PH) domains could be  involved in translocation of effector proteins to the membrane to obtain optimal phosphoinositide hydrolysis and  Ca<sup>2&#x0002b;</sup> mobilization. A likely candidate is Bruton's tyrosine  kinase, Btk, which has been shown to selectively interact  with PI(3,4,5)P<sub>3 </sub>vesicles via its PH domain (<xref ref-type="bibr" rid="B56">56</xref>). Indeed recent findings suggest that Btk is required for BCR-mediated Ca<sup>2&#x0002b;</sup> mobilization; in particular for extracellular influx  (Rawlings, D., personal communication). In this regard we  do see a higher antigen-mediated inductive tyrosine phosphorylation of Btk in our CD19-positive plasmacytoma cell  line than in the CD19-negative line, suggesting that CD19  may influence the activation of Btk (results not shown). Recently it was shown in both T cells and B cells that under  certain circumstances cell stimulation can lead to tyrosine  phosphorylation of PLC&#x003b3;, but no IP<sub>3</sub> production or calcium mobilization (<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B57">57</xref>&#x02013;<xref ref-type="bibr" rid="B59">59</xref>). These examples further underscores the concept that tyrosine phosphorylation of PLC&#x003b3;  is not in itself sufficient to induce maximal IP<sub>3</sub> generation.</p><p>A critical role for CD19 phosphorylation in BCR activation of PI3-kinase, IP<sub>3</sub> production, and calcium mobilization  is also supported by studies of Fc&#x003b3;RIIB1 signal transduction. We and others have recently shown that coligation of  BCR with Fc&#x003b3;RIIB1 leads to rapid dephosphorylation of  CD19 and failed PI3-kinase activation (<xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B61">61</xref>). Therefore,  Fc&#x003b3;RIIB1-mediated CD19 dephosphorylation appears to  prevent the normal contribution of CD19 to BCR signaling. Importantly, Fc&#x003b3;RIIB1 cocrosslinking with BCR also  results in aborted IP<sub>3</sub> production and reduced calcium mobilization. Thus, the calcium mobilization and IP<sub>3</sub> production phenotypes of the CD19-positive and -negative cell  lines are clearly reminiscent of the signaling phenotypes of  B cells stimulated with F(ab&#x02032;)<sub>2</sub> or intact antibodies, respectively (<xref ref-type="bibr" rid="B62">62</xref>, <xref ref-type="bibr" rid="B63">63</xref>). F(ab&#x02032;)<sub>2</sub> stimulation leads to a strong increase  in both intracellular and extracellular [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> mobilization,  comparable to the antigen-mediated calcium mobilization  in the CD19-positive cells, and a strong and sustained IP<sub>3</sub>  production. In contrast coengagement of the Fc&#x003b3;RIIB1 receptor by stimulation with intact antibodies only induces a  transient production of IP<sub>3</sub>, and calcium mobilization as  seen in the CD19-negative B cell line (Figs. <xref ref-type="fig" rid="F2">2</xref> and <xref ref-type="fig" rid="F3">3</xref>).  These data support a role for CD19 and its effector PI3-kinase in BCR-mediated PLC&#x003b3; activation and calcium  mobilization.</p><p>Since our studies indicate that CD19 is required for maximal (i.e., both primary and secondary phase) Ca<sup>2&#x0002b;</sup> mobilization, modulation of CD19 tyrosine phosphorylation, and  resulting modulation of [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> mobilization pattern may  be important in differentially regulating downstream signaling pathways such as activation of MAP kinase pathways,  transcription factors, and proliferation/apoptosis responses  (<xref ref-type="bibr" rid="B64">64</xref>, <xref ref-type="bibr" rid="B65">65</xref>). Recently it was demonstrated that the amplitude  and duration of Ca<sup>2&#x0002b;</sup> signals contribute to transcriptional  specificity (<xref ref-type="bibr" rid="B64">64</xref>). Such effects could at least in part be a consequence of the contribution of CD19, i.e., stimulation of  B lymphocytes with F(ab&#x02032;)<sub>2</sub>RAMIG, in which case CD19  is highly tyrosine phosphorylated, leads to a Ca<sup>2&#x0002b;</sup> spike and  a constant elevated second phase Ca<sup>2&#x0002b;</sup> response. In contrast  binding of immune complexes to Fc&#x003b3;RIIB1 and the BCR,  in which case CD19 tyrosine phosphorylation is decreased,  results in a Ca<sup>2&#x0002b;</sup> spike, but no prolonged second phase Ca<sup>2&#x0002b;</sup>  response triggering an effector output different from the  F(ab&#x02032;)<sub>2</sub>RAMIG stimulation. These modulations of the Ca<sup>2&#x0002b;</sup>  response may result in modulation of cell proliferation and  apoptosis. Splenic B cells proliferate in response to B cell  mitogens such as Staphylococcus aureus (SA) and anti-IgM.  The SA-proliferation response is partially inhibited by the  PI3-kinase inhibitor wortmannin (<xref ref-type="bibr" rid="B66">66</xref>), consistent with a role  of PI3-kinase in BCR-mediated proliferation responses.  CD19 activation may also be important for the regulation  of apoptosis. When immune complexes are bound to the  Fc&#x003b3;RIIB1 and the BCR, in which case CD19 tyrosine  phosphorylation is decreased, B cell proliferation is inhibited and cells undergo apoptosis (<xref ref-type="bibr" rid="B67">67</xref>). We hypothesize that  this inhibition of proliferation and induction of apoptosis is  a consequence of inhibition of PI3-kinase activity associated with CD19, leading to inhibition of downstream signaling pathways. Potentially Fc&#x003b3;RIIB1-mediated inhibition of CD19 tyrosine phosphorylation and PI3-kinase  activation could result in a failure to activate the serine/ threonine protein kinase Akt/PKB, which has been shown  to be a target of PI3-kinase (<xref ref-type="bibr" rid="B68">68</xref>&#x02013;<xref ref-type="bibr" rid="B70">70</xref>), and is known to protect cells against apoptosis (<xref ref-type="bibr" rid="B71">71</xref>&#x02013;<xref ref-type="bibr" rid="B73">73</xref>).</p><p>Here we have demonstrated a potential molecular basis  for the essential role played by CD19 in antigen-mediated  B cell activation, germinal center formation and generation  of immune responses. CD19 functions as a constitutive  component of the BCR signaling apparatus and is required  for antigen-mediated BCR stimulation of PI3-kinase activation and, via PI3-kinase activation, phosphoinositide hydrolysis, and calcium mobilization. In fact, this is the first  formal demonstration that CD19 modifies BCR signaling  directly. The findings have important biological implications  since CD19 and BCR expression are differentially regulated during B cell development. Variation of the ratio of  expression of these molecules may provide a mechanism to  vary the output of the receptor as a function of cell differentiation stage. Of potential importance in this context is  the fact that the contribution of CD19 to BCR signaling is  qualitative; it does not simply change the magnitude of the  signal.</p></sec></body><back><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>Expression levels of  surface markers on the plasmacytoma cell lines. Flow cytometric  analysis was performed on the  J558L&#x003bc;m3CD45<sup>&#x0002b;</sup> (<italic>dotted lines</italic>),  J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>CD19<sup>&#x0002b;</sup> (<italic>thick  lines</italic>), and J558L &#x003bc;m3CD45<sup>&#x0002b;</sup>  CD19<sup>&#x0002b;</sup> (Y<sup>484</sup>F,Y<sup>515</sup>F) (<italic>thin lines</italic>)  cell lines. Shown is staining with  secondary alone (<italic>A</italic>), biotinylated  b-7-6 anti-IgM (<italic>B</italic>), biotinylated  I32.5 anti-CD45 (<italic>C</italic>), or biotinylated HD37 anti-hCD19 (<italic>D</italic>) followed by PE-conjugated streptavidin.</p></caption><graphic xlink:href="JEM.971204f1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>The CD19-negative  and -positive J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>  plasmacytoma variants mobilize  [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> to different extent after  antigen stimulation. J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>CD19<sup>&#x02212;</sup> and J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>CD19<sup>&#x0002b;</sup> cells were loaded  with indo-1 AM, and analysis of  [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> initiated before antigen  stimulation (250 ng NP<sub>9</sub>BSA/ 10<sup>6</sup>cells/ml). Mean [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> (<italic>top</italic>)  and cells responding (<italic>bottom</italic>) after  antigen stimulation of J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>CD19<sup>&#x02212;</sup> and J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>CD19<sup>&#x0002b;</sup>. The analysis was  conducted under conditions of  60 nM (<italic>dotted line</italic>) or 1.3 mM  (<italic>solid line</italic>) extracellular free calcium concentration buffered as  calculated by the CalCalc program (<xref ref-type="bibr" rid="B74">74</xref>). [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> was calculated  according to Grynkiewicz et al.  (<xref ref-type="bibr" rid="B75">75</xref>). Approximately 600 cells were  analyzed per second. [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> in  resting cells is 100 nM.</p></caption><graphic xlink:href="JEM.971204f2"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>Antigen-induced  IP<sub>3</sub> and total inositol phosphate  release is greater in the CD19-positive than in CD19-negative  J558L&#x003bc;m3CD45<sup>&#x0002b;</sup> cells. (<italic>A</italic>)  Cells (10 &#x000d7; 10<sup>6</sup>/ml) were stimulated with 2.5 &#x003bc;g NP<sub>9</sub>BSA for  various times and the responses  terminated by addition of 100%  TCA (20% TCA final). After organic extraction the aqueous  phase was assayed for IP<sub>3</sub> content  in a [<sup>3</sup>H]IP<sub>3</sub> receptor binding inhibition assay (<named-content content-type="company" xlink:href="dupont">NEN-DuPont</named-content>).  The results are expressed as fold  increase of IP<sub>3</sub> release over basal  (3 pmol IP<sub>3</sub>/2.5 &#x000d7; 10<sup>6</sup> cell  equivalents). Shown is mean fold  increase from three independent  experiments &#x000b1; standard error.  (<italic>B</italic>) Cells were labeled with <italic>Myo</italic>- [2-<sup>3</sup>H(N)]-inositol (21.0 Ci/mmol; 2 &#x003bc;Ci/ml) in inositol-free medium containing 5% FCS at 10<sup>6</sup> cells/ml for 18 h and the generation of inositol phosphates was measured after stimulation of cells for 25 min with 2.5 &#x003bc;g NP<sub>9</sub>BSA/10<sup>7</sup> cells/ml. The fold increase in inositol phosphate release was calculated;  the two cell lines had comparable basal rates of inositol turnover as determined by the basal inositol phosphate release. Shown are the mean fold increases from  three independent experiments &#x000b1; standard error. Statistical significance was determined by JMP version 3.16 statistical software (SAS Institute, Cary, NC).</p></caption><graphic xlink:href="JEM.971204f3a"/><graphic xlink:href="JEM.971204f3b"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p>Tyrosine phosphorylation of signaling molecules upon  antigen stimulation of the CD19-negative and CD19-positive cell  lines. J558L&#x003bc;m3 CD45<sup>&#x0002b;</sup> variants  were stimulated for 1 min with  2.5 &#x003bc;g NP<sub>9</sub>BSA/10<sup>7</sup>cells/ml,  lysed, and intermediary signaling  molecules immunoprecipitated  with various antibodies and fractionated on 10% SDS-PAGE.  After electrophoretic transfer to  PVDF membrane, both anti-phosphotyrosine and anti-effector immunoblotting were performed. Data are representative  of at least three independent experiments.</p></caption><graphic xlink:href="JEM.971204f4"/></fig><fig position="float" id="F5"><label>Figure 5</label><caption><p>PI3-kinase activity is significantly increased only upon antigen stimulation of the CD19-positive J558L&#x003bc;m3CD45<sup>&#x0002b;</sup> cells. CD19-negative and CD19-positive J558L&#x003bc;m3CD45<sup>&#x0002b;</sup> cells were stimulated for 2  min with 1 &#x003bc;gNP<sub>9</sub>BSA/4 &#x000d7; 10<sup>6</sup>/ml, lysed and PI3-kinase immunoprecipitated with anti-p85 antibody. Immunoprecipitates were washed and  assayed for P-I3 kinase activity. Fold increase in PI3-kinase activity after  stimulation was determined using a PhosphorImager. The data shown is  the mean fold increase over basal in eight independent experiments &#x000b1;  standard error of the mean. Statistical significance was determined by JMP  version 3.16 statistical software (SAS Institute, Cary, NC).</p></caption><graphic xlink:href="JEM.971204f5"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Phenotypic Differences Between  J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>CD19<sup>&#x02212;</sup> and J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>CD19<sup>&#x0002b;</sup> Cell  Lines</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Signal transduction event</th><th rowspan="2"/><th colspan="5">Responding cell phenotype/condition</th></tr><tr><th>CD19<sup>&#x0002b;</sup></th><th/><th>CD19<sup>&#x02212;</sup></th><th/><th>CD19<sup>&#x0002b;</sup> with 25 nM wortmannin</th></tr></thead><tbody><tr><td align="left">Ig-&#x003b1;Tyr Phos</td><td/><td>&#x0002b;&#x0002b;&#x0002b;&#x0002b;</td><td/><td>&#x0002b;&#x0002b;&#x0002b;</td><td/><td>&#x0002b;&#x0002b;&#x0002b;&#x0002b;</td></tr><tr><td align="left">Lyn Tyr Phos</td><td/><td>&#x0002b;&#x0002b;&#x0002b;&#x0002b;</td><td/><td>&#x0002b;&#x0002b;&#x0002b;</td><td/><td>&#x0002b;&#x0002b;&#x0002b;&#x0002b;</td></tr><tr><td align="left">Syk Tyr Phos</td><td/><td>&#x0002b;&#x0002b;&#x0002b;&#x0002b;</td><td/><td>&#x0002b;&#x0002b;&#x0002b;</td><td/><td>&#x0002b;&#x0002b;&#x0002b;&#x0002b;</td></tr><tr><td align="left">PLC&#x003b3;l/PLC&#x003b3;2 Tyr Phos</td><td/><td>&#x0002b;&#x0002b;&#x0002b;&#x0002b;</td><td/><td>&#x0002b;&#x0002b;</td><td/><td>&#x0002b;&#x0002b;&#x0002b;</td></tr><tr><td align="left">IP<sub>3</sub> production</td><td/><td>&#x0002b;&#x0002b;&#x0002b;&#x0002b;</td><td/><td>&#x0002b;</td><td/><td>&#x0002b;</td></tr><tr><td align="left">[Ca<sup>2&#x0002b;</sup>]i mobilization</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Intracellular stores</td><td/><td>&#x0002b;&#x0002b;&#x0002b;&#x0002b;</td><td/><td>&#x0002b;&#x0002b;</td><td/><td>&#x0002b;&#x0002b;</td></tr><tr><td align="left">&#x02003;Influx</td><td/><td>&#x0002b;&#x0002b;&#x0002b;</td><td/><td>&#x02212;</td><td/><td>&#x02212;</td></tr><tr><td align="left">PI3-Kinase activation</td><td/><td>&#x0002b;&#x0002b;&#x0002b;&#x0002b;</td><td/><td>&#x0002b;</td><td/><td>&#x0002b;</td></tr></tbody></table></table-wrap><fig position="float" id="F6"><label>Figure 6</label><caption><p>Wortmannin inhibits the antigen-induced increase  in PI3-kinase activity, [Ca<sup>2&#x0002b;</sup>]<sub>i</sub>  mobilization and IP<sub>3</sub> generation  in the J558L&#x003bc;m3 CD45<sup>&#x0002b;</sup>CD19<sup>&#x0002b;</sup>  plasmacytoma. (<italic>A</italic>) Cells were  preincubated with DMSO (vehicle) or wortmannin at various  concentrations (in 0.2% final  DMSO concentration) for 25  min at 25&#x000b0;C, prewarmed for 4  min at 37&#x000b0;C, and then stimulated  for 2 min with 1 &#x003bc;g NP<sub>9</sub>BSA/4  &#x000d7; 10<sup>6</sup> cells/ml before analysis of  PI3-kinase activation as described in Fig, 4. Shown is the  mean fold increase in activity  over basal from four independent  experiments &#x000b1; standard error of  the mean. Asterisk indicates a statistical significance of <italic>P</italic> &#x0003c;0.05 determined by JMP 3.16 statistical  software. (<italic>B</italic>) To study the effects  of wortmannin on the calcium response, J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>CD19<sup>&#x0002b;</sup>  cells were Indo-1 AM loaded  and preincubated with DMSO  (vehicle) or wortmannin at various concentrations (resulting in  0.2% final DMSO) for 25 min at  25&#x000b0;C, prewarmed for 4 min at  37&#x000b0;C, and stimulated at arrow  with 250 ng NP<sub>9</sub>BSA/10<sup>6</sup> cells/ml. Shown is the mean [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> over time  with analysis of &#x0223c;600 cells/s. [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> in resting cells is 100 nM. (<italic>C</italic>)  J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>CD19<sup>&#x0002b;</sup> cells were preincubated with DMSO or increasing concentrations of wortmannin, prewarmed, and stimulated with  2.5 &#x003bc;g NP<sub>9</sub>BSA/10<sup>7</sup>/ml for 1 min before IP<sub>3</sub> production was measured  by the IP<sub>3 </sub>receptor binding inhibition assay. Shown is the mean fold increase over basal in three independent experiments &#x000b1; standard error of  the mean. Asterisk indicates a statistical significance of <italic>P</italic> &#x0003c;0.05 determined by JMP 3.16 statistical software.</p></caption><graphic xlink:href="JEM.971204f6"/></fig><fig position="float" id="F7"><label>Figure 7</label><caption><p>In the CD19-positive J558L&#x003bc;m3CD45<sup>&#x0002b;</sup> cells, antigen-induced tyrosine phosphorylation of PLC&#x003b3;1 and PLC&#x003b3;2 is  slightly inhibited by wortmannin, while Lyn, Ig-&#x003b1; and Syk  inductive tyrosine phosphorylation is insensitive to wortmannin.  J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>CD19<sup>&#x0002b;</sup> cells  were preincubated with DMSO  or increasing concentrations of  wortmannin, prewarmed and  stimulated for 1 min with  NP<sub>9</sub>BSA (2.5 &#x003bc;g/10<sup>7</sup> cells/ml)  and lysed. Immunoprecipitation,  SDS-PAGE fractionation and electrophoretic transfer were performed. For each immunoprecipitation, both anti-phosphotyrosine  and anti-effector immunoblots  are shown. Results are representative of at least three independent experiments.</p></caption><graphic xlink:href="JEM.971204f7"/></fig><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Percent Inhibtion of Maximal Responses by Wortmannin Preincubation</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th>IP<sub>3</sub> production</th><th/><th>PLC&#x003b3;1 tyrosine phosphorylation</th><th/><th>PLC&#x003b3;2 tyrosine phosphorylation</th></tr></thead><tbody><tr><td>10 nM</td><td/><td align="left">41.7 &#x000b1; 10.8% (<italic>n</italic> &#x0003d; 2)</td><td/><td align="left">18.2 &#x000b1; 5.6% (<italic>n</italic> &#x0003d; 2) </td><td/><td>16.3 &#x000b1; 4.4% (<italic>n</italic> &#x0003d; 6)</td></tr><tr><td>25 nM</td><td/><td align="left">91.5 &#x000b1; 8.6% (<italic>n</italic> &#x0003d; 2)</td><td/><td align="left">34.6 &#x000b1; 11.4% (<italic>n</italic> &#x0003d; 3)</td><td/><td>34.9 &#x000b1; 7.4% (<italic>n</italic> &#x0003d; 5)</td></tr><tr><td>50 nM</td><td/><td align="left">97.6 &#x000b1; 2.5% (<italic>n</italic> &#x0003d; 2)</td><td/><td align="left">44.7 &#x000b1; 10.2% (<italic>n</italic> &#x0003d; 3)</td><td/><td>58.4 &#x000b1; 3.8% (<italic>n</italic> &#x0003d; 6)</td></tr></tbody></table></table-wrap><fig position="float" id="F8"><label>Figure 8</label><caption><p>Mutant CD19 (CD19Y<sup>484</sup>F,Y<sup>515</sup>F) does not support antigen-induced [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> mobilization. J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>CD19<sup>&#x02212;</sup>, J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>  CD19<sup>&#x0002b;</sup> and J558L&#x003bc;m3CD45<sup>&#x0002b;</sup>CD19<sup>&#x0002b;</sup>(Y<sup>484</sup>F,Y<sup>515</sup>F) cells were loaded with  Indo-1 AM, and analysis of [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> initiated before antigen stimulation  (250 ng NP<sub>9</sub>BSA/10<sup>6</sup>cells/ml). Shown is the mean [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> over time with  analysis of &#x0223c;600 cells/s. [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> in resting cells is 100 nM.</p></caption><graphic xlink:href="JEM.971204f8"/></fig><fig position="float" id="F9"><label>Figure 9</label><caption><p>Antigen induction of [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> mobilization in splenic B cells  from normal mice is sensitive to wortmannin. Splenic B cells (&#x003c1; &#x02a7e;1.066)  were isolated from spleens of normal mice, and loaded with Indo-1 AM.  The cells were preincubated with DMSO or increasing concentrations of  wortmannin for 25 min at 25&#x000b0;C. They were then warmed to 37&#x000b0;C for 4  min and stimulated with 13.2 &#x003bc;g F(ab&#x02032;)<sub>2</sub>RAMIG/10<sup>6</sup>/ml (at arrow).  Shown is the mean [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> over time with analysis of &#x0223c;600 cells/s.  [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> in resting cells is 70 nM.</p></caption><graphic xlink:href="JEM.971204f9"/></fig><fig position="float" id="F10"><label>Figure 10</label><caption><p>BCR-mediated  stimulation of PI3-kinase activation is diminished in splenic B  cells from CD19<sup>&#x02212;&#x0002f;&#x02212;</sup> mice compared with CD19<sup>&#x0002b;/&#x0002b;</sup> littermates. Splenic B cells (&#x003c1; &#x02a7e;1.066)  were purified from spleens of  CD19<sup>&#x02212;&#x0002f;&#x02212;</sup> or CD19<sup>&#x0002b;/&#x0002b;</sup> mice, prewarmed, stimulated with F(ab&#x02032;)<sub>2</sub>  RAMIG (26.4 &#x003bc;g/5 &#x000d7; 10<sup>6</sup>/ml)  for 2 min, lysed, and then immunoprecipitated with an anti-p85  antibody. Immunoprecipitates  were washed and assayed for PI3-kinase activity. Fold increase in  PI3-kinase activity after stimulation was determined using a  PhosphorImager. (<italic>A</italic>) Primary  autoradiographic data from a representative experiment. (<italic>B</italic>) Mean fold increase over basal in three independent experiments &#x000b1; standard error of the mean.  Statistical significance was determined by JMP version 3.16 statistical software (SAS Institute).</p></caption><graphic xlink:href="JEM.971204f10b"/><graphic xlink:href="JEM.971204f10a"/></fig><fig position="float" id="F11"><label>Figure 11</label><caption><p>BCR-mediated [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> mobilization is reduced in splenic B  cells from CD19<sup>&#x02212;&#x0002f;&#x02212;</sup> mice compared with CD19<sup>&#x0002b;/&#x0002b;</sup> littermates at both  optimal and suboptimal doses of antibody. B cells (&#x003c1; &#x02a7e;1.066) were isolated from spleen of CD19<sup>&#x02212;&#x0002f;&#x02212;</sup> and CD19<sup>&#x0002b;/&#x0002b;</sup> mice and loaded with Indo-1  AM. [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> mobilization was monitored before and after stimulation of  the cells with F(ab&#x02032;)<sub>2</sub> RAMIG. (<italic>A</italic>) Cells were stimulated with 13 &#x003bc;g/10<sup>6</sup>  cells/ml; shown is an overlay of the [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> mobilization pattern in an experiment where splenic B cells from two CD19<sup>&#x02212;&#x0002f;&#x02212;</sup> and two CD19<sup>&#x0002b;/&#x0002b;</sup>  mice were compared independently. This experiment was performed 10  times with similar results. (<italic>B</italic>) Cells were stimulated with a suboptimal  dose of F(ab&#x02032;)<sub>2 </sub>RAMIG (1.3 &#x003bc;g/10<sup>6</sup> cells/ml). Shown is the mean [Ca<sup>2&#x0002b;</sup>]<sub>i</sub>  over time with analysis of &#x0223c;600 cells/s. [Ca<sup>2&#x0002b;</sup>]<sub>i</sub> in resting cells is 70 nM.</p></caption><graphic xlink:href="JEM.971204f11"/></fig></sec><ack><p>We thank Michael Reth for provision of the J558L&#x003bc;m3 cells, Thomas Tedder for the hCD19 cDNA, and  Marc Hertz for help with use of the JMP statistical analysis program, comments and reading of the manuscript.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fearon</surname><given-names>DT</given-names></name><name><surname>Carter</surname><given-names>RH</given-names></name></person-group><article-title>The CD19/CR2/ TAPA-1 complex of B lymphocytes: linking natural to acquired immunity</article-title><source>Ann Rev Immunol</source><year>1995</year><volume>13</volume><fpage>127</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">7542009</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>RH</given-names></name><name><surname>Doody</surname><given-names>GM</given-names></name><name><surname>Bolen</surname><given-names>JB</given-names></name><name><surname>Fearon</surname><given-names>DT</given-names></name></person-group><article-title>Membrane IgM-induced tyrosine phosphorylation of CD19 requires a CD19 domain that mediates association with components of the B cell antigen receptor complex</article-title><source>J Immunol</source><year>1997</year><volume>158</volume><fpage>3062</fpage><lpage>3069</lpage><pub-id pub-id-type="pmid">9120258</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tedder</surname><given-names>TF</given-names></name><name><surname>Isaacs</surname><given-names>CM</given-names></name></person-group><article-title>Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily</article-title><source>J  Immunol</source><year>1989</year><volume>143</volume><fpage>712</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">2472450</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roifman</surname><given-names>CM</given-names></name><name><surname>Ke</surname><given-names>S</given-names></name></person-group><article-title>CD19 is a substrate of the antigen receptor-associated protein tyrosine kinase in human B cells</article-title><source>Biochem Biophys Res Commun</source><year>1993</year><volume>194</volume><fpage>222</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">7687428</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uckun</surname><given-names>FM</given-names></name><name><surname>Burkhardt</surname><given-names>AL</given-names></name><name><surname>Jarvis</surname><given-names>L</given-names></name><name><surname>Jun</surname><given-names>X</given-names></name><name><surname>Stealey</surname><given-names>B</given-names></name><name><surname>Dibirdik</surname><given-names>I</given-names></name><name><surname>Myers</surname><given-names>DE</given-names></name><name><surname>Tuel</surname><given-names>AL</given-names></name><name><surname>Bolen</surname><given-names>JB</given-names></name></person-group><article-title>Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny</article-title><source>J Biol  Chem</source><year>1993</year><volume>268</volume><fpage>21172</fpage><lpage>21184</lpage><pub-id pub-id-type="pmid">7691807</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Noesel</surname><given-names>CJM</given-names></name><name><surname>Lankester</surname><given-names>AC</given-names></name><name><surname>van Schijndel</surname><given-names>GMW</given-names></name><name><surname>van Lier</surname><given-names>RAW</given-names></name></person-group><article-title>The CR2/CD19 complex on human B cells contains the src-family kinase Lyn</article-title><source>Intl Immunol</source><year>1993</year><volume>5</volume><fpage>699</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">7690241</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tedder</surname><given-names>TF</given-names></name><name><surname>Zhou</surname><given-names>LJ</given-names></name><name><surname>Engel</surname><given-names>P</given-names></name></person-group><article-title>The CD19/ CD21 signal transduction complex of B lymphocytes</article-title><source>Immunol Today</source><year>1994</year><volume>15</volume><fpage>437</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">7524521</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chalupny</surname><given-names>NJ</given-names></name><name><surname>Aruffo</surname><given-names>A</given-names></name><name><surname>Esselstyn</surname><given-names>JM</given-names></name><name><surname>Chan</surname><given-names>P-Y</given-names></name><name><surname>Bajorath</surname><given-names>J</given-names></name><name><surname>Blake</surname><given-names>J</given-names></name><name><surname>Gilliland</surname><given-names>LK</given-names></name><name><surname>Ledbetter</surname><given-names>JA</given-names></name><name><surname>Tepper</surname><given-names>MA</given-names></name></person-group><article-title>Specific binding of Fyn and phosphatidylinositol 3-kinase to the B cell surface glycoprotein CD19 through their src homology 2 domains</article-title><source>Eur J Immunol</source><year>1995</year><volume>25</volume><fpage>2978</fpage><lpage>2984</lpage><pub-id pub-id-type="pmid">7589101</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tuveson</surname><given-names>DA</given-names></name><name><surname>Carter</surname><given-names>RH</given-names></name><name><surname>Soltoff</surname><given-names>SP</given-names></name><name><surname>Fearon</surname><given-names>DT</given-names></name></person-group><article-title>CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase</article-title><source>Science</source><year>1993</year><volume>260</volume><fpage>986</fpage><lpage>989</lpage><pub-id pub-id-type="pmid">7684160</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>W-K</given-names></name><name><surname>Jarvis</surname><given-names>L</given-names></name><name><surname>LeBien</surname><given-names>TW</given-names></name></person-group><article-title>Signaling through CD19 activates Vav/mitogen-activated protein kinase pathway and induces formation of a CD19/Vav/phosphatidylinositol 3-kinase complex in human B cell precursors</article-title><source>J Biol Chem</source><year>1994</year><volume>269</volume><fpage>32514</fpage><lpage>32521</lpage><pub-id pub-id-type="pmid">7528218</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Songyang</surname><given-names>Z</given-names></name><name><surname>Shoelson</surname><given-names>SE</given-names></name><name><surname>McGlade</surname><given-names>J</given-names></name><name><surname>Olivier</surname><given-names>P</given-names></name><name><surname>Pawson</surname><given-names>T</given-names></name><name><surname>Bustelo</surname><given-names>XR</given-names></name><name><surname>Barbacid</surname><given-names>M</given-names></name><name><surname>Sabe</surname><given-names>H</given-names></name><name><surname>Hanafusa</surname><given-names>H</given-names></name><name><surname>Yi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav</article-title><source>Mol Cell Biol</source><year>1994</year><volume>14</volume><fpage>2777</fpage><lpage>2785</lpage><pub-id pub-id-type="pmid">7511210</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="other">Gilliland, L.K., G.L. Schieven, N.A. Norris, S.B. Kanner, A.  Aruffo, and J.A. Ledbetter. 1992. Lymphocyte lineage-restricted  tyrosine-phosphorylated proteins that bind PLC gamma 1  SH2 domains. <italic>J. Biol. Chem.</italic> 267, no. 19:13610&#x02013;13616.</citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chalupny</surname><given-names>NJ</given-names></name><name><surname>Kanner</surname><given-names>SB</given-names></name><name><surname>Schieven</surname><given-names>GL</given-names></name><name><surname>Wee</surname><given-names>S</given-names></name><name><surname>Gilliland</surname><given-names>LK</given-names></name><name><surname>Aruffo</surname><given-names>A</given-names></name><name><surname>Ledbetter</surname><given-names>JA</given-names></name></person-group><article-title>Tyrosine phosphorylation of CD19 in pre-B and mature B cells</article-title><source>EMBO  (Eur Mol Biol Organ) J</source><year>1993</year><volume>12</volume><fpage>2691</fpage><lpage>2696</lpage><pub-id pub-id-type="pmid">7687539</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>AK</given-names></name><name><surname>Kopicky</surname><given-names>BJ</given-names></name><name><surname>Carter</surname><given-names>RH</given-names></name><name><surname>Tuveson</surname><given-names>DA</given-names></name><name><surname>Tedder</surname><given-names>TF</given-names></name><name><surname>Fearon</surname><given-names>DT</given-names></name></person-group><article-title>Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19</article-title><source>J Exp Med</source><year>1991</year><volume>173</volume><fpage>55</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">1702139</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bradbury</surname><given-names>LE</given-names></name><name><surname>Kansas</surname><given-names>GS</given-names></name><name><surname>Levy</surname><given-names>S</given-names></name><name><surname>Evans</surname><given-names>RL</given-names></name><name><surname>Tedder</surname><given-names>TF</given-names></name></person-group><article-title>The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules</article-title><source>J Immunol</source><year>1992</year><volume>149</volume><fpage>2841</fpage><lpage>2850</lpage><pub-id pub-id-type="pmid">1383329</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="other">Matsumoto, A.K., D.R. Martin, R.H. Carter, L.B. Klickstein, J.M. Ahearn, and D.T. Fearon. 1993. Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B  lymphocytes. <italic>J. Exp. Med.</italic> 178,:1407&#x02013;1417.</citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lankester</surname><given-names>AC</given-names></name><name><surname>van Schijndel</surname><given-names>GMW</given-names></name><name><surname>Rood</surname><given-names>PML</given-names></name><name><surname>Verhoeven</surname><given-names>AJ</given-names></name><name><surname>van Lier</surname><given-names>RAW</given-names></name></person-group><article-title>B cell antigen receptor cross-linking induces tyrosine phosphorylation and membrane translocation of a multimeric Shc complex that is augmented by CD19 co-ligation</article-title><source>Eur J Immunol</source><year>1994</year><volume>24</volume><fpage>2818</fpage><lpage>2825</lpage><pub-id pub-id-type="pmid">7525306</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lankester</surname><given-names>AC</given-names></name><name><surname>Rood</surname><given-names>PML</given-names></name><name><surname>van Schijudel</surname><given-names>GMW</given-names></name><name><surname>Hoodbrink</surname><given-names>B</given-names></name><name><surname>Verhoeven</surname><given-names>AJ</given-names></name><name><surname>van Lier</surname><given-names>RAW</given-names></name></person-group><article-title>Alteration of B-cell antigen receptor signaling by CD19 co-ligation. A study with bispecific antibodies</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>22326</fpage><lpage>22330</lpage><pub-id pub-id-type="pmid">8798392</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>RH</given-names></name><name><surname>Tuveson</surname><given-names>DA</given-names></name><name><surname>Park</surname><given-names>DJ</given-names></name><name><surname>Rhee</surname><given-names>SG</given-names></name><name><surname>Fearon</surname><given-names>DT</given-names></name></person-group><article-title>The CD19 complex of B lymphocytes. Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex</article-title><source>J Immunol</source><year>1991</year><volume>147</volume><fpage>3663</fpage><lpage>3671</lpage><pub-id pub-id-type="pmid">1719083</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>RH</given-names></name><name><surname>Fearon</surname><given-names>DT</given-names></name></person-group><article-title>CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes</article-title><source>Science</source><year>1992</year><volume>256</volume><fpage>105</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">1373518</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dempsey</surname><given-names>PW</given-names></name><name><surname>Allison</surname><given-names>ME</given-names></name><name><surname>Akkaraju</surname><given-names>S</given-names></name><name><surname>Goodnow</surname><given-names>CC</given-names></name><name><surname>Fearon</surname><given-names>DT</given-names></name></person-group><article-title>C3d of complement as a molecular adjuvant: bridging innate and acquired immunity</article-title><source>Science</source><year>1996</year><volume>271</volume><fpage>348</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">8553069</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krop</surname><given-names>I</given-names></name><name><surname>Shaffer</surname><given-names>AL</given-names></name><name><surname>Fearon</surname><given-names>DT</given-names></name><name><surname>Schlissel</surname><given-names>MS</given-names></name></person-group><article-title>The signaling activity of murine CD19 is regulated during B cell development</article-title><source>J Immunol</source><year>1996</year><volume>157</volume><fpage>48</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">8683154</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ledbetter</surname><given-names>JA</given-names></name><name><surname>Rabinovitch</surname><given-names>PS</given-names></name><name><surname>June</surname><given-names>CH</given-names></name><name><surname>Song</surname><given-names>CW</given-names></name><name><surname>Clark</surname><given-names>EA</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>Antigen-independent regulation of cytoplasmic calcium in B cells with a 12-kD B-cell growth factor and anti-CD19</article-title><source>Proc Natl Acad Sci USA</source><year>1988</year><volume>85</volume><fpage>1897</fpage><lpage>1901</lpage><pub-id pub-id-type="pmid">2450350</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pesando</surname><given-names>JM</given-names></name><name><surname>Bouchard</surname><given-names>LS</given-names></name><name><surname>McMaster</surname><given-names>BE</given-names></name></person-group><article-title>CD19 is functionally and physically associated with surface immunoglobulin</article-title><source>J Exp Med</source><year>1989</year><volume>170</volume><fpage>2159</fpage><lpage>2163</lpage><pub-id pub-id-type="pmid">2479707</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rijkers</surname><given-names>GT</given-names></name><name><surname>Griffioen</surname><given-names>AW</given-names></name><name><surname>Zegers</surname><given-names>BJ</given-names></name><name><surname>Cambier</surname><given-names>JC</given-names></name></person-group><article-title>Ligation of membrane immunoglobulin leads to inactivation of the signal-transducing ability of membrane immunoglobulin, CD19, CD21, and B-cell gp95</article-title><source>Proc Natl  Acad Sci USA</source><year>1990</year><volume>87</volume><fpage>8766</fpage><lpage>8770</lpage><pub-id pub-id-type="pmid">1701054</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Engel</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>L-J</given-names></name><name><surname>Ord</surname><given-names>DC</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Koller</surname><given-names>B</given-names></name><name><surname>Tedder</surname><given-names>TF</given-names></name></person-group><article-title>Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule</article-title><source>Immunity</source><year>1995</year><volume>3</volume><fpage>39</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">7542548</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rickert</surname><given-names>RC</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name><name><surname>Roes</surname><given-names>J</given-names></name></person-group><article-title>Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice</article-title><source>Nature</source><year>1995</year><volume>376</volume><fpage>352</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">7543183</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Justement</surname><given-names>LB</given-names></name><name><surname>Campbell</surname><given-names>KS</given-names></name><name><surname>Chien</surname><given-names>NC</given-names></name><name><surname>Cambier</surname><given-names>JC</given-names></name></person-group><article-title>Regulation of B cell antigen receptor signal transduction and phosphorylation by CD45</article-title><source>Science</source><year>1991</year><volume>252</volume><fpage>1839</fpage><lpage>1842</lpage><pub-id pub-id-type="pmid">1648262</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Couture</surname><given-names>C</given-names></name><name><surname>Baier</surname><given-names>G</given-names></name><name><surname>Oetken</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>S</given-names></name><name><surname>Telford</surname><given-names>D</given-names></name><name><surname>Marie-Cardine</surname><given-names>A</given-names></name><name><surname>Baier-Bitterlich</surname><given-names>G</given-names></name><name><surname>Fischer</surname><given-names>S</given-names></name><name><surname>Burn</surname><given-names>P</given-names></name><name><surname>Altman</surname><given-names>A</given-names></name><name><surname>Mustelin</surname><given-names>T</given-names></name></person-group><article-title>Activation of p56<sup>lck</sup> by  p72<sup>syk</sup>through physical association and N-terminal tyrosine phosphorylation</article-title><source>Mol Cell Biol</source><year>1994</year><volume>14</volume><fpage>5249</fpage><lpage>5258</lpage><pub-id pub-id-type="pmid">7518561</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whitman</surname><given-names>M</given-names></name><name><surname>Downes</surname><given-names>CP</given-names></name><name><surname>Keeler</surname><given-names>M</given-names></name><name><surname>Keller</surname><given-names>T</given-names></name><name><surname>Cantley</surname><given-names>L</given-names></name></person-group><article-title>Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate</article-title><source>Nature</source><year>1988</year><volume>332</volume><fpage>644</fpage><lpage>646</lpage><pub-id pub-id-type="pmid">2833705</pub-id></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>KS</given-names></name><name><surname>Hager</surname><given-names>EJ</given-names></name><name><surname>Friedrich</surname><given-names>RJ</given-names></name><name><surname>Cambier</surname><given-names>JC</given-names></name></person-group><article-title>IgM antigen receptor complex contains phosphoprotein products of B29 and mb-1 genes</article-title><source>Proc Natl Acad Sci  USA</source><year>1991</year><volume>88</volume><fpage>3982</fpage><lpage>3986</lpage><pub-id pub-id-type="pmid">2023945</pub-id></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hombach</surname><given-names>J</given-names></name><name><surname>Leclercq</surname><given-names>L</given-names></name><name><surname>Radbruch</surname><given-names>A</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name><name><surname>Reth</surname><given-names>M</given-names></name></person-group><article-title>A novel 34-kd protein co-isolated with the IgM molecule in surface IgM-expressing cells</article-title><source>EMBO (Eur  Mol Biol Organ) J</source><year>1988</year><volume>7</volume><fpage>3451</fpage><lpage>3456</lpage><pub-id pub-id-type="pmid">3264786</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L-J</given-names></name><name><surname>Ord</surname><given-names>DC</given-names></name><name><surname>Omori</surname><given-names>SA</given-names></name><name><surname>Tedder</surname><given-names>TF</given-names></name></person-group><article-title>Structure of the genes encoding the CD19 antigen of human and mouse B lymphocytes</article-title><source>Immunogenetics</source><year>1992</year><volume>35</volume><fpage>102</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">1370948</pub-id></citation></ref><ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Steeber</surname><given-names>DA</given-names></name><name><surname>Jansen</surname><given-names>PJ</given-names></name><name><surname>Tedder</surname><given-names>TF</given-names></name></person-group><article-title>CD19 expression levels regulate B lymphocyte development</article-title><source>J Immunol</source><year>1997</year><volume>158</volume><fpage>4662</fpage><lpage>4669</lpage><pub-id pub-id-type="pmid">9144478</pub-id></citation></ref><ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krop</surname><given-names>I</given-names></name><name><surname>de Fougerolles</surname><given-names>AR</given-names></name><name><surname>Hardy</surname><given-names>RR</given-names></name><name><surname>Allison</surname><given-names>M</given-names></name><name><surname>Schlissel</surname><given-names>MS</given-names></name><name><surname>Fearon</surname><given-names>DT</given-names></name></person-group><article-title>Self-renewal of B-1 lymphocytes is dependent on CD19</article-title><source>Eur J Immunol</source><year>1996</year><volume>26</volume><fpage>238</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">8566073</pub-id></citation></ref><ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Putney</surname><given-names>JJ</given-names></name></person-group><article-title>Excitement about calcium signaling in inexcitable cells</article-title><source>Science</source><year>1993</year><volume>262</volume><fpage>676</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">8235587</pub-id></citation></ref><ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>MR</given-names></name><name><surname>Campbell</surname><given-names>KS</given-names></name><name><surname>Kazlauskas</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>SA</given-names></name><name><surname>Hertz</surname><given-names>M</given-names></name><name><surname>Potter</surname><given-names>TA</given-names></name><name><surname>Pleiman</surname><given-names>C</given-names></name><name><surname>Cambier</surname><given-names>JC</given-names></name></person-group><article-title>The B cell antigen receptor complex: association of Ig-alpha and Ig-beta with distinct cytoplasmic effectors</article-title><source>Science</source><year>1992</year><volume>258</volume><fpage>123</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">1439759</pub-id></citation></ref><ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>DA</given-names></name><name><surname>Chan</surname><given-names>VWF</given-names></name><name><surname>Datta</surname><given-names>SK</given-names></name><name><surname>DeFranco</surname><given-names>AL</given-names></name></person-group><article-title>B-cell antigen receptor motifs have redundant signaling capabilities and bind the tyrosine kinases PTK72, Lyn and Fyn</article-title><source>Curr Biol</source><year>1993</year><volume>3</volume><fpage>645</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">15335855</pub-id></citation></ref><ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>SA</given-names></name><name><surname>Pleiman</surname><given-names>CM</given-names></name><name><surname>Pao</surname><given-names>L</given-names></name><name><surname>Schneringer</surname><given-names>J</given-names></name><name><surname>Hippen</surname><given-names>K</given-names></name><name><surname>Cambier</surname><given-names>JC</given-names></name></person-group><article-title>Phosphorylated immunoreceptor signaling motifs (ITAMs) exhibit unique abilities to bind and activate Lyn and syk tyrosine kinases</article-title><source>J Immunol</source><year>1995</year><volume>155</volume><fpage>4596</fpage><lpage>4603</lpage><pub-id pub-id-type="pmid">7594458</pub-id></citation></ref><ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cambier</surname><given-names>JC</given-names></name></person-group><article-title>Antigen and Fc receptor signaling</article-title><source>J Immunol</source><year>1995</year><volume>155</volume><fpage>3281</fpage><lpage>3285</lpage><pub-id pub-id-type="pmid">7561018</pub-id></citation></ref><ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pao</surname><given-names>LI</given-names></name><name><surname>Bedzyk</surname><given-names>WD</given-names></name><name><surname>Persin</surname><given-names>C</given-names></name><name><surname>Cambier</surname><given-names>JC</given-names></name></person-group><article-title>Molecular targets of CD45 in B cell antigen receptor signal transduction</article-title><source>J Immunol</source><year>1997</year><volume>158</volume><fpage>1116</fpage><lpage>1124</lpage><pub-id pub-id-type="pmid">9013950</pub-id></citation></ref><ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pleiman</surname><given-names>CM</given-names></name><name><surname>Hertz</surname><given-names>WM</given-names></name><name><surname>Cambier</surname><given-names>JC</given-names></name></person-group><article-title>Activation of phosphatidylinositol-3&#x02032; kinase by Src-family kinase SH3 binding to the p85 subunit</article-title><source>Science</source><year>1994</year><volume>263</volume><fpage>1609</fpage><lpage>1612</lpage><pub-id pub-id-type="pmid">8128248</pub-id></citation></ref><ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wymann</surname><given-names>MP</given-names></name><name><surname>Bulgarelli-Leva</surname><given-names>G</given-names></name><name><surname>Zvelebil</surname><given-names>MJ</given-names></name><name><surname>Pirola</surname><given-names>L</given-names></name><name><surname>Vanhaesebroeck</surname><given-names>B</given-names></name><name><surname>Waterfield</surname><given-names>MD</given-names></name><name><surname>Panayotou</surname><given-names>G</given-names></name></person-group><article-title>Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction</article-title><source>Mol Cell Biol</source><year>1996</year><volume>16</volume><fpage>1722</fpage><lpage>1733</lpage><pub-id pub-id-type="pmid">8657148</pub-id></citation></ref><ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vlahos</surname><given-names>CJ</given-names></name><name><surname>Matter</surname><given-names>WF</given-names></name><name><surname>Hui</surname><given-names>KY</given-names></name><name><surname>Brown</surname><given-names>RF</given-names></name></person-group><article-title>A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)</article-title><source>J  Biol Chem</source><year>1994</year><volume>269</volume><fpage>5241</fpage><lpage>5248</lpage><pub-id pub-id-type="pmid">8106507</pub-id></citation></ref><ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>LJ</given-names></name><name><surname>Smith</surname><given-names>HM</given-names></name><name><surname>Waldschmidt</surname><given-names>TJ</given-names></name><name><surname>Schwating</surname><given-names>R</given-names></name><name><surname>Daley</surname><given-names>J</given-names></name><name><surname>Tedder</surname><given-names>TF</given-names></name></person-group><article-title>Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B-lymphocyte development</article-title><source>Mol Cell Biol</source><year>1994</year><volume>14</volume><fpage>3884</fpage><lpage>3894</lpage><pub-id pub-id-type="pmid">7515149</pub-id></citation></ref><ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Ono</surname><given-names>N</given-names></name><name><surname>Steeber</surname><given-names>DA</given-names></name><name><surname>Pisetsky</surname><given-names>DS</given-names></name><name><surname>Tedder</surname><given-names>TF</given-names></name></person-group><article-title>CD19 regulates b lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity</article-title><source>J Immunol</source><year>1996</year><volume>157</volume><fpage>4371</fpage><lpage>4378</lpage><pub-id pub-id-type="pmid">8906812</pub-id></citation></ref><ref id="B47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Steeber</surname><given-names>DA</given-names></name><name><surname>Tedder</surname><given-names>TF</given-names></name></person-group><article-title>The CD19 signal transduction molecule is a response regulator of B-lymphocyte differentiation</article-title><source>Proc Natl Acad Sci USA</source><year>1995</year><volume>92</volume><fpage>11558</fpage><lpage>11562</lpage><pub-id pub-id-type="pmid">8524803</pub-id></citation></ref><ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakanishi</surname><given-names>S</given-names></name><name><surname>Catt</surname><given-names>KJ</given-names></name><name><surname>Balla</surname><given-names>T</given-names></name></person-group><article-title>Inhibition of agonist-stimulated inositol 1,4,5-trisphosphate production and calcium signaling by the myosin light chain kinase inhibitor, wortmannin</article-title><source>J Biol Chem</source><year>1994</year><volume>269</volume><fpage>6528</fpage><lpage>6535</lpage><pub-id pub-id-type="pmid">8120005</pub-id></citation></ref><ref id="B49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barker</surname><given-names>SA</given-names></name><name><surname>Caldwell</surname><given-names>KK</given-names></name><name><surname>Hall</surname><given-names>A</given-names></name><name><surname>Martinez</surname><given-names>AM</given-names></name><name><surname>Pfeiffer</surname><given-names>JR</given-names></name><name><surname>Oliver</surname><given-names>JM</given-names></name><name><surname>Wilson</surname><given-names>BS</given-names></name></person-group><article-title>Wortmannin blocks lipid and protein kinase activities associated with PI 3-kinase and inhibits a subset of responses induced by Fc epsilon R1 cross-linking</article-title><source>Mol Biol Cell</source><year>1995</year><volume>6</volume><fpage>1145</fpage><lpage>1158</lpage><pub-id pub-id-type="pmid">8534912</pub-id></citation></ref><ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nishibe</surname><given-names>S</given-names></name><name><surname>Wahl</surname><given-names>MI</given-names></name><name><surname>Hernandez-Sotomayor</surname><given-names>SMT</given-names></name><name><surname>Tonks</surname><given-names>NK</given-names></name><name><surname>Rhee</surname><given-names>SG</given-names></name><name><surname>Carpenter</surname><given-names>G</given-names></name></person-group><article-title>Increase of the catalytic activity of phospholipase C-&#x003b3;1 by tyrosine phosphorylation</article-title><source>Science</source><year>1990</year><volume>250</volume><fpage>1253</fpage><lpage>1256</lpage><pub-id pub-id-type="pmid">1700866</pub-id></citation></ref><ref id="B51"><label>51</label><citation citation-type="other">Cantley, L.C., K.R. Auger, C. Carpenter, B. Duckworth, A.  Graziani, R. Kapeller, and S. Soltoff. 1991. Oncogenes and signal transduction. <italic>Cell.</italic> 64:281&#x02013;302 (erratum published 65:915).</citation></ref><ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rameh</surname><given-names>LE</given-names></name><name><surname>Chen</surname><given-names>CS</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name></person-group><article-title>Phosphatidylinositol (3,4,5)P<sub>3</sub>interacts with SH2 domains and modulates PI 3-kinase association with tyrosine-phosphorylated proteins</article-title><source>Cell</source><year>1995</year><volume>83</volume><fpage>821</fpage><lpage>830</lpage><pub-id pub-id-type="pmid">8521499</pub-id></citation></ref><ref id="B53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>SG</given-names></name><name><surname>Bae</surname><given-names>YS</given-names></name></person-group><article-title>Regulation of phosphoinositide-specific phospholipase C isozymes</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>15045</fpage><lpage>15048</lpage><pub-id pub-id-type="pmid">9182519</pub-id></citation></ref><ref id="B54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Atkinson</surname><given-names>TP</given-names></name><name><surname>Kaliner</surname><given-names>MA</given-names></name><name><surname>Hohman</surname><given-names>RJ</given-names></name></person-group><article-title>Phospholipase C-&#x003b3;1 is translocated to the membrane of rat basophilic leukemia cells in response to aggregation of IgE receptors</article-title><source>J Immunol</source><year>1992</year><volume>148</volume><fpage>2194</fpage><lpage>2200</lpage><pub-id pub-id-type="pmid">1312104</pub-id></citation></ref><ref id="B55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Atkinson</surname><given-names>TP</given-names></name><name><surname>Lee</surname><given-names>CW</given-names></name><name><surname>Rhee</surname><given-names>SG</given-names></name><name><surname>Hohman</surname><given-names>RJ</given-names></name></person-group><article-title>Orthovanadate induces translocation of phospholipase C-gamma 1 and -gamma 2 in permeabilized mast cells</article-title><source>J Immunol</source><year>1993</year><volume>151</volume><fpage>1448</fpage><lpage>1455</lpage><pub-id pub-id-type="pmid">7687631</pub-id></citation></ref><ref id="B56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salim</surname><given-names>K</given-names></name><name><surname>Bottomley</surname><given-names>MJ</given-names></name><name><surname>Querfurth</surname><given-names>E</given-names></name><name><surname>Zvelebil</surname><given-names>MJ</given-names></name><name><surname>Gout</surname><given-names>I</given-names></name><name><surname>Scaife</surname><given-names>R</given-names></name><name><surname>Margolis</surname><given-names>RL</given-names></name><name><surname>Gigg</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>CIE</given-names></name><name><surname>Driscoll</surname><given-names>PC</given-names></name><etal/></person-group><article-title>Distinct specificity in the recognition of phosphoinositides by the pleckstrin homology domains of dynamin and Bruton's tyrosine kinase</article-title><source>EMBO (Eur Mol  Biol Organ) J</source><year>1996</year><volume>15</volume><fpage>6241</fpage><lpage>6250</lpage><pub-id pub-id-type="pmid">8947047</pub-id></citation></ref><ref id="B57"><label>57</label><citation citation-type="other">Rigley, K., P. Slocombe, K. Proudfoot, S. Wahid, K. Mandair, and C. Bebbington. 1995. Human p59fyn(T) regulates  OKT3-induced calcium influx by a mechanism distinct from  PIP2 hydrolysis in Jurkat T cells. <italic>J. Immunol.</italic> 154:1136&#x02013;1145  (erratum published 154:4223).</citation></ref><ref id="B58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Motto</surname><given-names>DG</given-names></name><name><surname>Musci</surname><given-names>MA</given-names></name><name><surname>Ross</surname><given-names>SE</given-names></name><name><surname>Koretsky</surname><given-names>GA</given-names></name></person-group><article-title>Tyrosine phosphorylation of Grb2-associated proteins correlates with phospholipase C&#x003b3;1 activation in T cells</article-title><source>Mol  Cell Biol</source><year>1996</year><volume>16</volume><fpage>2823</fpage><lpage>2829</lpage><pub-id pub-id-type="pmid">8649391</pub-id></citation></ref><ref id="B59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>WA</given-names></name><name><surname>Pleiman</surname><given-names>CM</given-names></name><name><surname>Beaufils</surname><given-names>P</given-names></name><name><surname>Wegener</surname><given-names>A-M</given-names></name><name><surname>Malissen</surname><given-names>B</given-names></name><name><surname>Cambier</surname><given-names>JC</given-names></name></person-group><article-title>Qualitatively distinct signaling through T cell antigen receptor subunits</article-title><source>Eur J Immunol</source><year>1997</year><volume>27</volume><fpage>707</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">9079813</pub-id></citation></ref><ref id="B60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kiener</surname><given-names>PA</given-names></name><name><surname>Lioubin</surname><given-names>MN</given-names></name><name><surname>Rohrschneider</surname><given-names>LR</given-names></name><name><surname>Ledbetter</surname><given-names>JA</given-names></name><name><surname>Nadler</surname><given-names>SG</given-names></name><name><surname>Diegel</surname><given-names>ML</given-names></name></person-group><article-title>Co-ligation of the antigen and Fc receptors gives rise to the selective modulation of intracellular signaling in B cells</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>3838</fpage><lpage>3844</lpage><pub-id pub-id-type="pmid">9013643</pub-id></citation></ref><ref id="B61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hippen</surname><given-names>KL</given-names></name><name><surname>Buhl</surname><given-names>AM</given-names></name><name><surname>D'Ambrosio</surname><given-names>D</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Persin</surname><given-names>C</given-names></name><name><surname>Cambier</surname><given-names>JC</given-names></name></person-group><article-title>Fc&#x003b3;RIIB1 inhibition of BCR  mediated phosphoinositide hydrolysis and Ca<sup>2&#x0002b;</sup>mobilization is integrated by CD19 dephosphorylation</article-title><source>Immunity</source><year>1997</year><volume>7</volume><fpage>49</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">9252119</pub-id></citation></ref><ref id="B62"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bijsterbosch</surname><given-names>MK</given-names></name><name><surname>Klaus</surname><given-names>GG</given-names></name></person-group><article-title>Crosslinking of surface immunoglobulin and Fc receptors on B lymphocytes inhibits stimulation of inositol phospholipid breakdown via the antigen receptors</article-title><source>J Exp Med</source><year>1985</year><volume>162</volume><fpage>1825</fpage><lpage>1836</lpage><pub-id pub-id-type="pmid">3877778</pub-id></citation></ref><ref id="B63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>HA</given-names></name><name><surname>Greenblatt</surname><given-names>D</given-names></name><name><surname>Taylor</surname><given-names>CW</given-names></name><name><surname>Putney</surname><given-names>JW</given-names></name><name><surname>Tsien</surname><given-names>RY</given-names></name><name><surname>Finkelman</surname><given-names>FD</given-names></name><name><surname>Chused</surname><given-names>TM</given-names></name></person-group><article-title>The B lymphocyte calcium response to anti-Ig is diminished by membrane immunoglobulin cross-linkage to the Fc gamma receptor</article-title><source>J Immunol</source><year>1987</year><volume>138</volume><fpage>1712</fpage><lpage>1718</lpage><pub-id pub-id-type="pmid">2950170</pub-id></citation></ref><ref id="B64"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dolmetsch</surname><given-names>RE</given-names></name><name><surname>Lewis</surname><given-names>RS</given-names></name><name><surname>Goodnow</surname><given-names>CC</given-names></name><name><surname>Healy</surname><given-names>JI</given-names></name></person-group><article-title>Differential activation of transcription factors  induced by Ca<sup>2&#x0002b;</sup>response amplitude and duration</article-title><source>Nature</source><year>1997</year><volume>386</volume><fpage>855</fpage><lpage>858</lpage><pub-id pub-id-type="pmid">9126747</pub-id></citation></ref><ref id="B65"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Healy</surname><given-names>JI</given-names></name><name><surname>Dolmetsch</surname><given-names>RE</given-names></name><name><surname>Timmermann</surname><given-names>LA</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name><name><surname>Thomas</surname><given-names>ML</given-names></name><name><surname>Crabtree</surname><given-names>GR</given-names></name><name><surname>Lewis</surname><given-names>RS</given-names></name><name><surname>Goodnow</surname><given-names>CC</given-names></name></person-group><article-title>Different nuclear signals are activated by the B cell receptor during positive versus negative signaling</article-title><source>Immunity</source><year>1997</year><volume>6</volume><fpage>419</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">9133421</pub-id></citation></ref><ref id="B66"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aagaard-Tillery</surname><given-names>KM</given-names></name><name><surname>Jelinek</surname><given-names>DF</given-names></name></person-group><article-title>Phosphatidylinositol 3-kinase activation in normal human B lymphocytes</article-title><source>J Immunol</source><year>1996</year><volume>156</volume><fpage>4543</fpage><lpage>4554</lpage><pub-id pub-id-type="pmid">8648095</pub-id></citation></ref><ref id="B67"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ashman</surname><given-names>RF</given-names></name><name><surname>Peckham</surname><given-names>D</given-names></name><name><surname>Stunz</surname><given-names>LL</given-names></name></person-group><article-title>Fc receptor off-signal in the B cell involves apoptosis</article-title><source>J Immunol</source><year>1996</year><volume>157</volume><fpage>5</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">8683155</pub-id></citation></ref><ref id="B68"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burgering</surname><given-names>BMT</given-names></name><name><surname>Coffer</surname><given-names>PJ</given-names></name></person-group><article-title>Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction</article-title><source>Nature</source><year>1995</year><volume>376</volume><fpage>599</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">7637810</pub-id></citation></ref><ref id="B69"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Datta</surname><given-names>K</given-names></name><name><surname>Bellacosa</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>TO</given-names></name><name><surname>Tsichlis</surname><given-names>PN</given-names></name></person-group><article-title>Akt is a direct target of the phosphatidylinositol 3-kinase</article-title><source>J  Biol Chem</source><year>1996</year><volume>271</volume><fpage>30835</fpage><lpage>30839</lpage><pub-id pub-id-type="pmid">8940066</pub-id></citation></ref><ref id="B70"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Franke</surname><given-names>TF</given-names></name><name><surname>Kaplan</surname><given-names>DR</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><name><surname>Toker</surname><given-names>A</given-names></name></person-group><article-title>Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate</article-title><source>Science</source><year>1997</year><volume>275</volume><fpage>665</fpage><lpage>668</lpage><pub-id pub-id-type="pmid">9005852</pub-id></citation></ref><ref id="B71"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dudek</surname><given-names>H</given-names></name><name><surname>Datta</surname><given-names>SR</given-names></name><name><surname>Franke</surname><given-names>TF</given-names></name><name><surname>Birnbaum</surname><given-names>MJ</given-names></name><name><surname>Yao</surname><given-names>R</given-names></name><name><surname>Cooper</surname><given-names>GM</given-names></name><name><surname>Segal</surname><given-names>RA</given-names></name><name><surname>Kaplan</surname><given-names>DR</given-names></name><name><surname>Greenberg</surname><given-names>ME</given-names></name></person-group><article-title>Regulation of neuronal survival by the serine-threonine protein kinase Akt</article-title><source>Science</source><year>1997</year><volume>275</volume><fpage>661</fpage><lpage>665</lpage><pub-id pub-id-type="pmid">9005851</pub-id></citation></ref><ref id="B72"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kauffmann-Zeh</surname><given-names>A</given-names></name><name><surname>Rodriguez-Viciana</surname><given-names>P</given-names></name><name><surname>Ulrich</surname><given-names>E</given-names></name><name><surname>Gilbert</surname><given-names>C</given-names></name><name><surname>Coffer</surname><given-names>P</given-names></name><name><surname>Downward</surname><given-names>J</given-names></name><name><surname>Evan</surname><given-names>G</given-names></name></person-group><article-title>Suppression of c-Myc-induced apoptosis by Ras signaling through PI(3)K and PKB</article-title><source>Nature</source><year>1997</year><volume>385</volume><fpage>544</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">9020362</pub-id></citation></ref><ref id="B73"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kulik</surname><given-names>G</given-names></name><name><surname>Klippel</surname><given-names>A</given-names></name><name><surname>Weber</surname><given-names>MJ</given-names></name></person-group><article-title>Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt</article-title><source>Mol Cell Biol</source><year>1997</year><volume>17</volume><fpage>1595</fpage><lpage>1606</lpage><pub-id pub-id-type="pmid">9032287</pub-id></citation></ref><ref id="B74"><label>74</label><citation citation-type="other">CalCalc&#x02014;A Program to Calculate Calcium Concentrations  in the Presence of EGTA Department of Biochemistry, Colorado State University, Fort Collins, Colorado.</citation></ref><ref id="B75"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grynkiewicz</surname><given-names>G</given-names></name><name><surname>Poenie</surname><given-names>M</given-names></name><name><surname>Tsien</surname><given-names>RY</given-names></name></person-group><article-title>A new  generation of Ca<sup>2&#x0002b;</sup>indicators with greatly improved fluorescence properties</article-title><source>J Biol Chem</source><year>1985</year><volume>260</volume><fpage>3440</fpage><lpage>3450</lpage><pub-id pub-id-type="pmid">3838314</pub-id></citation></ref></ref-list><fn-group><fn><p><sup>1</sup>&#x02009;<italic>Abbreviations used in this paper:</italic> BCR, B cell antigen receptor; IP<sub>3</sub>, inositol-1,4,5-trisphosphate; ITAM, immunoreceptor tyrosine based activation motif; NP, nitrophenol; PH, pleckstrin homology; PI, phosphatidylinositol; PI3-kinase, phosphatidylinositol 3-kinase.</p></fn><fn><p>A.M. Buhl is a Leukemia Society Research Fellow. J.C. Cambier is an Ida and Cecil Green Professor of Cell  Biology. These studies were supported by the US Public Health Service.</p></fn></fn-group></back></article>


